How to assess dementia risk

Abstract

The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the assessment of dementia risk in a middle-aged individual within a specific time frame, e.g., within 5, 10, 15, and / or 20 years. In one aspect, the present disclosure provides biomarkers that can be used alone or in various combinations to assess dementia risk within 5, 10, 15, and / or 20 years. In another aspect, a method is provided for assessing dementia risk in a middle-aged individual within 5, 10, 15, and / or 20 years, the method comprising detecting at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers presented in Table 6 in a biological sample from the individual.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application Nos. 63 / 389,214, filed July 14, 2022, and 63 / 446,402, filed February 17, 2023, each of which is incorporated by reference herein in its entirety for all purposes.

[0002] Field This application relates generally to methods for detecting biomarkers and assessing an individual's risk of dementia, and more specifically to one or more biomarkers, methods, devices, reagents, systems, and kits used to assess an individual's risk of developing dementia, e.g., within 5, 10, 15, and / or 20 years. [Background technology]

[0003] The following discussion provides a summary of information relevant to the present application and is not an admission that any of the information provided herein or publications referenced herein is prior art to the present application.

[0004] Dementia is a group of disorders characterized by a decline in cognitive abilities beyond those expected to accompany normal aging. The global prevalence of dementia in men and women over the age of 60 is estimated at 4.7% and 6.9%, respectively, in North America. The most common form of dementia is Alzheimer's disease, which accounts for 60-80% of dementia cases and is the sixth leading cause of death. Alzheimer's disease currently affects more than 6 million adults in the United States, a number expected to double over the next 30 years. While early-onset or familial dementia typically occurs before age 65 and is associated with a high genetic burden, dementia onset after age 65 is usually considered "sporadic."

[0005] Symptomatic features of dementia are clinical changes in memory, thinking, and other cognitive abilities reported by either the patient or their caregiver. Diagnosing dementia based on DSM-5 criteria typically involves a comprehensive neurocognitive assessment battery administered over a period of time to assess functional decline. This screening also takes into account the patient's history of psychiatric disorders, medications, laboratory test results, and an informant interview to rule out other possible causes of cognitive impairment. To determine the underlying cause of dementia, additional, more invasive evaluations are often performed to identify symptoms associated with dementia subtypes, including neuroimaging, spinal fluid evaluation of biomarkers, or serological assessment. For example, Alzheimer's disease is associated with the neuronal accumulation of beta-amyloid plaques and tau tangles, while dementia with Lewy bodies is associated with alpha-synuclein aggregation.

[0006] Although several therapeutic agents are commonly prescribed to individuals with dementia and may temporarily improve cognition, these drugs do not halt or slow the progression of the underlying neuropathological damage. A new class of Alzheimer's disease drugs targeting beta-amyloid has been expedited for approval by the FDA in recent years and has shown favorable preliminary findings in early-stage clinical trials in patients with early Alzheimer's disease and mild cognitive impairment.

[0007] The greatest risk factor for dementia is age. Estimates of Alzheimer's disease prevalence increase from 5.3% in people aged 65–74 to 13.8% in people aged 75–84 and over 30% in people over 85. For both genders, the average age of onset of any new dementia case in the United States is 83.7 years. As life expectancy increases and the aging population expands, the expected prevalence of Alzheimer's disease and the number of people with Alzheimer's disease are projected to increase significantly in the coming decades (Figure 1).

[0008] Other risk factors that increase the likelihood of dementia include a family history of dementia, and multiple modifiable lifestyle factors, including those related to cardiovascular disease, obesity, and diabetes.Common genetic polymorphisms known to increase the risk of dementia include the polymorphisms of the APOE gene that encode mutations in the ε2, ε3, and ε4 alleles, which are associated with Alzheimer's disease, cerebrovascular dysfunction, and Lewy body disease.The ε2 allele is thought to be neuroprotective, the ε3 allele is neutral, and the ε4 allele is thought to be risk-related.

[0009] While the United States Preventive Services Task Force (USPSTF) determined that there is no conclusive evidence for or against routine screening for dementia in asymptomatic adults, the USPSTF acknowledged the need for early identification of cognitive impairment. Because dementia develops slowly and is known to have a long prodromal phase before the onset of cognitive symptoms, the neuropathophysiology of Alzheimer's disease (referred to as preclinical Alzheimer's disease) may begin to take shape 15 to 20 years before the onset of cognitive symptoms, when plaques and tangles become evident in the brain. Current screening tests are limited to detecting current dementia pathophysiology or progression when symptoms are present, at which point it may be too late to prevent or provide appropriate treatment.

[0010] Given the lack of available evidence-based treatment options for dementia, risk interventions (healthy diet, exercise, social and cognitive stimulation, reduction of vascular disease risk factors) are likely to be the most effective way to reduce the future prevalence of dementia.

[0011] Currently, there are few long-term predictive screening tests for dementia. Recently, the FDA approved a direct-to-consumer test offered by 23andMe®, which reports an individual's risk of late-onset Alzheimer's disease by assessing the number of APOE4 gene variants an individual possesses. Several clinical risk calculators exist that are based on a combination of demographic factors, personal medical and family history, and lifestyle factors. However, these risk calculators and genetic factors do not change over time and often require self-reported variables. Currently, no clinical risk calculator is widely used as a standard of care in medical practice.

[0012] The development of proteomic models for determining dementia risk is highly desirable, and therefore, there is a need for biomarkers, methods, devices, reagents, systems, and kits that allow prediction of dementia onset within a specific time frame, e.g., within a 5, 10, 15, and / or 20 year period. Summary of the Invention

[0013] The present application includes biomarkers, methods, reagents, devices, systems, and kits for predicting the risk of developing dementia within a specific time frame, e.g., within a 20-year period. In some embodiments, methods are provided for identifying subjects at risk of developing dementia. In some embodiments, methods are provided for detecting the levels of N biomarker proteins in a sample.

[0014] In some embodiments there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of a CILP2 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, The method wherein the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0015] In some embodiments, there is provided a method of detecting levels of N biomarker proteins in a sample, comprising obtaining the sample from the subject and detecting the level of each of the N biomarker proteins in the sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least The method of claim 1, wherein the N biomarker proteins are 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0016] In some embodiments, a method of determining whether a subject is at risk of developing dementia within a 20 year period comprises detecting a level of a PTN biomarker protein and a level of each of N biomarker proteins in a sample from the subject, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0017] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of a PH biomarker protein and a level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0018] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of Notch1 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, The method wherein the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0019] In some embodiments, a method of determining whether a subject is at risk of developing dementia within a 20 year period comprises detecting a level of a NADK biomarker protein and a level of each of N biomarker proteins in a sample from the subject, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0020] In some embodiments, a method of determining whether a subject is at risk of developing dementia within a 20 year period comprises detecting in a sample from the subject a level of a CDON biomarker protein and a level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0021] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of MP2K2 biomarker protein and a level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least The method wherein the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0022] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of H2A3 biomarker protein and a level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0023] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of an IGFALS biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, The method wherein the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0024] In some embodiments there is provided a method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of S100A13 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17 , at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0025] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject the level of a CILP2 biomarker protein and the level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0026] In some embodiments, methods of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period comprise detecting a level of a PTN biomarker protein and a level of each of N biomarker proteins in a sample from the subject, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0027] In some embodiments, a method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period comprises detecting a level of a PH biomarker protein and a level of each of N biomarker proteins in a sample from the subject, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76 7, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0028] In some embodiments, methods of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period comprise detecting in a sample from the subject the level of Notch1 biomarker protein and the level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least the N biomarker proteins are at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0029] In some embodiments, methods of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period comprise detecting in a sample from the subject a level of a NADK biomarker protein and a level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least the N biomarker proteins are at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0030] In some embodiments, methods of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period comprise detecting in a sample from the subject a level of a CDON biomarker protein and a level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least the N biomarker proteins are at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0031] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject the level of MP2K2 biomarker protein and the level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0032] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject the level of H2A3 biomarker protein and the level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least the N biomarker proteins are at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0033] In some embodiments, methods of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period comprise detecting the level of an IGFALS biomarker protein and the level of each of N biomarker proteins in a sample from the subject, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least the N biomarker proteins are at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0034] In some embodiments, there is provided a method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject the level of S100A13 biomarker protein and the level of each of N biomarker proteins, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least The method wherein the N biomarker proteins are at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0035] In some embodiments, N is 2-25, or N is 3-25, or N is 4-25, or N is 5-25, or N is 6-25, or N is 7-25, or N is 8-25, or N is 9-25, or N is 10-25, or N is 11-25, or N is 12-25, or N is 13-25, or N is 14-25, or N is 15-25. In some embodiments, N is 2, or N is 3, or N is 4, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10, or N is 11, or N is 12, or N is 13, or N is 14, or N is 15, or N is 16, or N is 17, or N is 18, or N is 19, or N is 20, or N is 21, or N is 22, or N is 23, or N is 24, or N is 25.

[0036] In some embodiments, each of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG. In some embodiments, at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13. In some embodiments, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 of the N protein biomarkers are selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13. In some embodiments, two of the N biomarker proteins are CILP2 and H2A3, or two of the N biomarker proteins are CILP2 and IGFALS, or two of the N biomarker proteins are CILP2 and MP2K2, or two of the N biomarker proteins are CILP2 and NADK, or two of the N biomarker proteins are CILP2 and Notch1, or two of the N biomarker proteins are CILP2 and PH, or two of the N biomarker proteins are CILP2 and PTN, or two of the N biomarker proteins are CILP2 and S100A13, or two of the N biomarker proteins are CILP2 and CDON.In some embodiments, two of the N biomarker proteins are PTN and PH, or two of the N biomarker proteins are PTN and S100A13, or two of the N biomarker proteins are PTN and Notch1, or two of the N biomarker proteins are PTN and NADK, or two of the N biomarker proteins are PTN and MP2K2, or two of the N biomarker proteins are PTN and IGFALS, or two of the N biomarker proteins are PTN and H2A3, or two of the N biomarker proteins are PTN and CDON. In some embodiments, two of the N biomarker proteins are PH and Notch1, or two of the N biomarker proteins are PH and NADK, or two of the N biomarker proteins are PH and CDON, or two of the N biomarker proteins are PH and MP2K2, or two of the N biomarker proteins are PH and H2A3, or two of the N biomarker proteins are PH and IGFALS, or two of the N biomarker proteins are PH and S100A13. In some embodiments, two of the N biomarker proteins are Notch1 and NADK, or two of the N biomarker proteins are Notch1 and CDON, or two of the N biomarker proteins are Notch1 and MP2K2, or two of the N biomarker proteins are Notch1 and H2A3, or two of the N biomarker proteins are Notch1 and IGFALS, or two of the N biomarker proteins are Notch1 and S100A13.In some embodiments, two of the N biomarker proteins are NADK and CDON, or two of the N biomarker proteins are NADK and MP2K2, or two of the N biomarker proteins are NADK and H2A3, or two of the N biomarker proteins are NADK and IGFALS, or two of the N biomarker proteins are NADK and S100A13. In some embodiments, two of the N biomarker proteins are CDON and MP2K2, or two of the N biomarker proteins are CDON and H2A3, or two of the N biomarker proteins are CDON and IGFALS, or two of the N biomarker proteins are CDON and S100A13. In some embodiments, two of the N biomarker proteins are MP2K2 and H2A3, or two of the N biomarker proteins are MP2K2 and IGFALS, or two of the N biomarker proteins are MP2K2 and S100A13. In some embodiments, two of the N biomarker proteins are H2A3 and IGFALS, or two of the N biomarker proteins are H2A3 and S100A13. In some embodiments, two of the N biomarker proteins are IGFALS and S100A13.

[0037] In some embodiments, the sample is a blood sample, plasma sample, or serum sample. In some embodiments, the subject is 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 years of age or older. In some embodiments, detection is performed using mass spectrometry, an aptamer-based assay, and / or an antibody-based assay. In some embodiments, the method comprises contacting biomarker proteins of a sample or multiple samples with a set of biomarker capture reagents, where each biomarker capture reagent of the set of biomarker capture reagents specifically binds to a different biomarker protein to be detected. In some embodiments, each biomarker capture reagent is an antibody or an aptamer. In some embodiments, each biomarker capture reagent is an aptamer. In some embodiments, at least one aptamer is a slow off-rate aptamer. In some embodiments, the at least one slow off-rate aptamer comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 modified nucleotides. In some embodiments, each slow off-rate aptamer binds to its target protein with a dissociation rate (t1 / 2) of 20 minutes or less, 30 minutes or less, 60 minutes or less, 90 minutes or less, 120 minutes or less, 150 minutes or less, 180 minutes or less, 210 minutes or less, or 240 minutes or less. In some embodiments, the level of each biomarker protein determined is determined by relative fluorescence units (RFU) or protein concentration.

[0038] In some embodiments, determining the risk of developing dementia within a 5, 10, 15, and / or 20 year period is based on input of the measured levels of N biomarker proteins into a statistical model. In some embodiments, determining includes analyzing the levels of the N biomarker proteins using an accelerated time to death (AFT) model with a Weibull distribution. In some embodiments, the model has an area under the curve (AUC) selected from at least 0.65, at least 0.66, at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.75, at least 0.8, at least 0.85, at least 0.9, or at least 0.95. In some embodiments, the model provides absolute risk probabilities of being diagnosed with dementia within 5, 10, 15, and / or 20 years. In some embodiments, the model provides calculations of relative risk probabilities of being diagnosed with dementia within 5, 10, 15, and / or 20 years. In some embodiments, the relative risk is a range of values used to predict the onset of dementia within 5, 10, 15, and / or 20 years. In some embodiments, the relative risk is a low-to-high range. In some embodiments, the relative risk ranges from 0.25 to 6.67. In some embodiments, the model provides absolute probability or relative risk predictions of dementia onset within a 5, 10, 15, and / or 20-year time period based on the level of each of proteins selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0039] In some embodiments, subjects are identified as being at risk for developing dementia within a 5-, 10-, 15-, and / or 20-year time period. In some embodiments, the at-risk subjects are administered a treatment. In some embodiments, the treatment includes implementing a healthy diet, exercise, social and cognitive stimulation, and / or reducing vascular disease risk factors. In some embodiments, the at-risk subjects are monitored at one or more additional time points to determine their risk for developing dementia within a 5-, 10-, 15-, and / or 20-year time period. In some embodiments, the at-risk subjects are stratified into preventive treatment trials. In some embodiments, a second diagnostic test is administered to the at-risk subjects. In some embodiments, the second diagnostic test is an APOE diagnostic test. In some embodiments, subjects at risk for developing dementia within a 5-, 10-, 15-, and / or 20-year time period are identified for purposes of determining life and / or financial planning. In some embodiments, one or more additional biomarkers associated with dementia are identified in subjects at risk of or with dementia.

[0040] In some embodiments, risk is determined over a 5-year period. In some embodiments, risk is determined over a 10-year period. In some embodiments, risk is determined over a 15-year period. In some embodiments, risk is determined over a 20-year period.

[0041] In some embodiments, a kit is provided, the kit comprising N biomarker protein capture reagents, where N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, wherein at least one of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

[0042] In some embodiments, N is 2-25, or N is 3-25, or N is 4-25, or N is 5-25, or N is 6-25, or N is 7-25, or N is 8-25, or N is 9-25, or N is 10-25, or N is 11-25, or N is 12-25, or N is 13-25, or N is 14-25, or N is 15-25. In some embodiments, N is 2, or N is 3, or N is 4, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10, or N is 11, or N is 12, or N is 13, or N is 14, or N is 15, or N is 16, or N is 17, or N is 18, or N is 19, or N is 20, or N is 21, or N is 22, or N is 23, or N is 24, or N is 25. In some embodiments, each of the N biomarker protein capture reagents specifically binds to a different biomarker protein. In some embodiments, each of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG. In some embodiments, at least one of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

[0043] In some embodiments, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or N at least 10 of the N biomarker protein capture reagents specifically bind to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

[0044] In some embodiments, two of the N biomarker protein capture reagents specifically bind CILP2 and H2A3, or two of the N biomarker protein capture reagents specifically bind CILP2 and IGFALS, or two of the N biomarker protein capture reagents specifically bind CILP2 and MP2K2, or two of the N biomarker protein capture reagents specifically bind CILP2 and NADK, or two of the N biomarker protein capture reagents specifically bind CILP2 and Notch1, or two of the N biomarker protein capture reagents specifically bind CILP2 and PH, or two of the N biomarker protein capture reagents specifically bind CILP2 and PTN, or two of the N biomarker protein capture reagents specifically bind CILP2 and S100A13, or two of the N biomarker protein capture reagents specifically bind CILP2 and CDON.

[0045] In some embodiments, two of the N biomarker protein capture reagents specifically bind PTN and PH, or two of the N biomarker protein capture reagents specifically bind PTN and S100A13, or two of the N biomarker protein capture reagents specifically bind PTN and Notch1, or two of the N biomarker protein capture reagents specifically bind PTN and NADK, or two of the N biomarker protein capture reagents specifically bind PTN and MP2K2, or two of the N biomarker protein capture reagents specifically bind PTN and IGFALS, or two of the N biomarker protein capture reagents specifically bind PTN and H2A3, or two of the N biomarker protein capture reagents specifically bind PTN and CDON.

[0046] In some embodiments, two of the N biomarker protein capture reagents specifically bind PH and Notch1, or two of the N biomarker protein capture reagents specifically bind PH and NADK, or two of the N biomarker protein capture reagents specifically bind PH and CDON, or two of the N biomarker protein capture reagents specifically bind PH and MP2K2, or two of the N biomarker protein capture reagents specifically bind PH and H2A3, or two of the N biomarker protein capture reagents specifically bind PH and IGFALS, or two of the N biomarker protein capture reagents specifically bind PH and S100A13.

[0047] In some embodiments, two of the N biomarker protein capture reagents specifically bind Notch1 and NADK, or two of the N biomarker protein capture reagents specifically bind Notch1 and CDON, or two of the N biomarker protein capture reagents specifically bind Notch1 and MP2K2, or two of the N biomarker protein capture reagents specifically bind Notch1 and H2A3, or two of the N biomarker protein capture reagents specifically bind Notch1 and IGFALS, or two of the N biomarker protein capture reagents specifically bind Notch1 and S100A13.

[0048] In some embodiments, two of the N biomarker protein capture reagents specifically bind NADK and CDON, or two of the N biomarker protein capture reagents specifically bind NADK and MP2K2, or two of the N biomarker protein capture reagents specifically bind NADK and H2A3, or two of the N biomarker protein capture reagents specifically bind NADK and IGFALS, or two of the N biomarker protein capture reagents specifically bind NADK and S100A13.

[0049] In some embodiments, two of the N biomarker protein capture reagents specifically bind CDON and MP2K2, or two of the N biomarker protein capture reagents specifically bind CDON and H2A3, or two of the N biomarker protein capture reagents specifically bind CDON and IGFALS, or two of the N biomarker protein capture reagents specifically bind CDON and S100A13.

[0050] In some embodiments, two of the N biomarker protein capture reagents specifically bind MP2K2 and H2A3, or two of the N biomarker protein capture reagents specifically bind MP2K2 and IGFALS, or two of the N biomarker protein capture reagents specifically bind MP2K2 and S100A13. In some embodiments, two of the N biomarker protein capture reagents specifically bind H2A3 and IGFALS, or two of the N biomarker protein capture reagents specifically bind H2A3 and S100A13. In some embodiments, two of the N biomarker protein capture reagents specifically bind IGFALS and S100A13.

[0051] In some embodiments, a kit is provided that includes N biomarker protein capture reagents, wherein the kit includes biomarker protein capture reagents for performing any of the methods described herein. In some embodiments, each of the N biomarker protein capture reagents is an antibody or an aptamer. In some embodiments, each biomarker protein capture reagent is an aptamer. In some embodiments, at least one aptamer is a slow off-rate aptamer. In some embodiments, the at least one slow off rate aptamer comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 modified nucleotides. In some embodiments, each slow off rate aptamer has a dissociation rate (t) of 20 minutes or less, 30 minutes or less, 60 minutes or less, 90 minutes or less, 120 minutes or less, 150 minutes or less, 180 minutes or less, 210 minutes or less, or 240 minutes or less. 1 / 2 ) and binds to its target protein. In some embodiments, the kit is used to detect N biomarker proteins in a sample from a subject, hi some embodiments, the kit is used to determine whether a subject is at risk for developing dementia within a 5, 10, 15, and / or 20 year period. [Brief explanation of the drawings]

[0052] [Figure 1] This shows the predicted number of Alzheimer's disease patients (by age group) in the United States from 2020 to 2060. [Figure 2] Calibration plots of Kaplan-Meier estimates of observed event rates against model-predicted probabilities, stratified by risk deciles, are shown. [Figure 3] Specific nucleobase modifications that can be used in aptamers are shown. [Figure 4] 1 illustrates an exemplary computer system for use with various computer-implemented methods described herein. [Figure 5] 1 shows a flowchart of a method for assessing the risk of dementia according to one or more embodiments. DETAILED DESCRIPTION OF THE INVENTION

[0053] Reference will now be made in detail to exemplary embodiments of the invention. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that it is not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents which may be included within the scope of the present invention as defined by the appended claims.

[0054] One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention and are within the scope of the present invention, and is in no way limited to the methods and materials described.

[0055] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, particular methods, devices, and materials are described below.

[0056] All publications, published patent documents, and patent applications cited in this application are indicative of the state of the art of the art(s) to which this application pertains. All publications, published patent documents, and patent applications cited herein are incorporated by reference to the same extent as if each individual publication, published patent document, or patent application was specifically and individually indicated to be incorporated by reference herein.

[0057] As used in this application, including the appended claims, unless the content clearly dictates otherwise, the singular forms "a," "an," and "the" include plural references and are used interchangeably with "at least one" and "one or more." Thus, reference to a "SOMAmer" includes mixtures of SOMAmers, reference to a "probe" includes mixtures of probes, and so forth.

[0058] As used herein, the term "about" refers to minor modifications or variations of a numerical value such that the basic function of the item to which the numerical value is related remains unchanged.

[0059] As used herein, the terms "comprises," "comprising," "includes," "including," "contains," "containing," and all variations thereof, are intended to cover a non-exclusive inclusion, whereby a process, method, product-by-process, or composition of matter that comprises, includes, or contains an element or set of elements not only includes those elements, but may also include other elements not expressly listed or that are inherent in such process, method, product-by-process, or composition of matter.

[0060] The present application includes biomarkers, methods, devices, reagents, systems, and kits for predicting the risk of dementia within a predetermined time period, e.g., 5, 10, 15, and / or 20 years. In some embodiments, the prediction of dementia risk is for subjects in middle age, e.g., 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 years of age or older.

[0061] The terms "biological sample," "sample," and "test sample" are used interchangeably herein to refer to any substance, biological fluid, tissue, or cell obtained from or otherwise derived from an individual. Examples include blood (e.g., whole blood, white blood cells, peripheral blood mononuclear cells, buffy coat, plasma, and serum), dried blood spots (e.g., from infants), sputum, tears, mucus, nasal washings, nasal aspirates, exhaled breath, urine, semen, saliva, peritoneal washings, ascites, cyst fluid, cerebrospinal fluid, amniotic fluid, glandular fluid, pancreatic juice, lymphatic fluid, pleural fluid, nipple aspirate, bronchial aspirate, bronchial brush, synovial fluid, joint aspirate, organ secretions, cells, cell extracts, and cerebrospinal fluid. Examples also include fractions separated for any of the above experiments. For example, a blood sample can be fractionated into serum, plasma, or fractions containing specific types of blood cells, such as red blood cells or leukocytes (white blood cells). Optionally, the sample may be a combination of samples from an individual, such as a combination of tissue and liquid samples. The term "biological sample" also includes materials containing homogenized solid material, such as from a stool sample, tissue sample, or tissue biopsy. The term "biological sample" also includes materials from tissue culture or cell culture. Any suitable method for obtaining a biological sample may be used, and exemplary methods include, for example, phlebotomy, swab (e.g., oral swab), and fine needle aspiration biopsy. Exemplary tissues amenable to fine needle aspiration include lymph node, lung, pulmonary lavage fluid, BAL (bronchoalveolar lavage), thyroid, breast, pancreas, and liver. Samples may also be collected by, for example, microdissection (e.g., laser capture microdissection (LCM) or laser microdissection (LMD)), bladder washing, smear (e.g., PAP smear), or ductal lavage. A "biological sample" obtained from or derived from an individual also includes any such sample processed by any suitable method after being obtained from the individual.

[0062] It should further be understood that the biological sample may be obtained by taking biological samples from multiple individuals and pooling them, or by pooling aliquots of each individual's biological sample. The pooled sample may be treated as a sample from a single individual, and if a high or low risk of dementia is confirmed in the pooled sample, each individual's biological sample may be retested to determine which individual(s) are at high or low risk of dementia.

[0063] For purposes of this specification, the phrase "data attributable to a biological sample from an individual" is intended to mean that the data in some form has been obtained from or generated using the subject biological sample of that individual. The data may have been reformatted, modified, or have their values altered to some extent after generation, such as by converting units from one measurement system to another, but the data is understood to have been obtained from or generated using the biological sample.

[0064] "Target," "target molecule," and "analyte" are used interchangeably herein to refer to any molecule of interest that may be present in a biological sample. A "molecule of interest" includes any minor changes to a particular molecule, such as, in the case of a protein, minor changes in amino acid sequence, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component, that do not substantially change the identity of the molecule. A "target molecule," "target," or "analyte" is one or a set of copies of a single molecule or multimolecular structure. "Multiple target molecules," "multiple targets," and "multiple analytes" refer to a set of two or more such molecules. Exemplary target molecules include proteins, polypeptides, nucleic acids, carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, affibodies, antibody mimetics, viruses, pathogens, toxic substances, substrates, metabolites, transition state analogs, cofactors, inhibitors, drugs, dyes, nutrients, growth factors, cells, tissues, and any fragment or portion of any of the foregoing. In some embodiments, the target molecule is a protein, in which case the target molecule may be referred to as a "target protein."

[0065] As used herein, "capture agent" or "capture reagent" refers to a molecule capable of specifically binding to a biomarker. "Target protein capture reagent" refers to a molecule capable of specifically binding to a target protein. Non-limiting exemplary capture reagents include aptamers, antibodies, adnectins, ankyrins, other antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small molecules, nucleic acids, lectins, ligand-binding receptors, imprinted polymers, avimers, peptidomimetics, hormone receptors, cytokine receptors, synthetic receptors, and modified forms and fragments of any of the above-mentioned capture reagents. In some embodiments, the capture reagent is selected from an aptamer and an antibody.

[0066] As used herein, "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. Polymers can be linear or branched, can contain modified amino acids, and can be interrupted by non-amino acids. The terms also encompass amino acid polymers that are naturally modified or modified by intervention, e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids) and other modifications known in the art. Polypeptides can be single chains or associated chains. Also included within the definition are precursor proteins and intact mature proteins; peptides or polypeptides derived from mature proteins; protein fragments; splice variants; recombinant proteins; protein variants with amino acid modifications, deletions, or substitutions; digests; and post-translational modifications, e.g., glycosylation, acetylation, phosphorylation, and the like.

[0067] The term "antibody" refers to full-length antibodies of any species, as well as fragments and derivatives of such antibodies, including Fab fragments, F(ab')2 fragments, single-chain antibodies, Fv fragments, and single-chain Fv fragments. The term "antibody" also refers to synthetically derived antibodies, such as antibodies and fragments derived by phage display, affibodies, nanobodies, etc.

[0068] As used herein, "marker" and "biomarker" and "feature" are used interchangeably to refer to a target molecule that is indicative of or symptomatic of a normal or abnormal process in an individual, or that is indicative of or symptomatic of a disease or other condition in an individual. More specifically, a "marker" or "biomarker" or "feature" is an anatomical, physiological, biochemical, or molecular parameter that is associated with the presence of a particular physiological condition or process, whether normal or abnormal, and, if abnormal, whether chronic or acute. Biomarkers can be detected and measured by a variety of methods, including laboratory assays and medical imaging. When a biomarker is a protein, the expression of the corresponding gene can be used as a surrogate for the amount or presence or absence of the corresponding protein biomarker in a biological sample, or the methylation status of the gene encoding the biomarker or the protein that controls the expression of the biomarker can be used. In certain embodiments, a feature is an analyte / SOMAmer reagent that is another predictor in a statistical model.

[0069] As used herein, "biomarker value," "value," "biomarker level," "feature level," and "level" are used interchangeably to refer to a measurement obtained using any analytical method to detect a biomarker in a biological sample, and indicating the presence, absence, absolute amount or concentration, relative amount or concentration, titer, level, expression level, ratio of measured levels, etc. of a biomarker in a biological sample, relating to, or corresponding to, a biomarker in a biological sample. The exact nature of a "value" or "level" depends on the specific design and components of the particular analytical method used to detect the biomarker.

[0070] If a biomarker indicates or is symptomatic of an abnormal process or disease or other condition in an individual, the biomarker is generally described as being either overexpressed or underexpressed compared to an expression level or value of the biomarker that indicates or is symptomatic of the absence of a normal process or disease or other condition in the individual. "Upregulated," "upregulated," "overexpression," "overexpressed," and any variations thereof are used interchangeably to refer to a value or level of a biomarker in a biological sample that exceeds the value or level (or range of values or levels) of that biomarker typically detected in a similar biological sample from a healthy or normal individual. The term can also refer to a value or level of a biomarker in a biological sample that exceeds the value or level (or range of values or levels) of that biomarker that can be detected at different stages of a particular disease.

[0071] "Downregulated," "downregulated," "underexpressed," "underexpressed," and any variations thereof, are used interchangeably to refer to a value or level of a biomarker in a biological sample that is less than the value or level (or range of values or levels) of that biomarker that is typically detected in a similar biological sample from a healthy or normal individual. The terms can also refer to a value or level of a biomarker in a biological sample that is less than the value or level (or range of values or levels) of that biomarker that can be detected at different stages of a particular disease.

[0072] Furthermore, a biomarker that is either overexpressed or underexpressed may also be referred to as being "differentially expressed" or having a "differential level" or "differential value" compared to a "normal" expression level or value of that biomarker that is indicative of or symptomatic of a normal process or the absence of a disease or other condition in an individual. Thus, "differential expression" of a biomarker may also be referred to as a variation from the "normal" expression level of that biomarker.

[0073] The terms "differential gene expression" and "differential expression" are used interchangeably to refer to genes (or their corresponding protein expression products) whose expression is activated to higher or lower levels in subjects suffering from a particular disease or condition compared to expression in normal or control subjects. This term also encompasses genes (or their corresponding protein expression products) whose expression is activated to higher or lower levels at different stages of the same disease or condition. It should also be understood that differentially expressed genes may be activated or inhibited at the nucleic acid or protein level, or may be subject to alternative splicing to result in different polypeptide products. Such differences may be evidenced by a variety of changes, including mRNA levels, surface expression, secretion, or other distribution of polypeptides. Differential gene expression may involve a comparison of expression between two or more genes or their gene products; or a comparison of the expression ratios between two or more genes or their gene products; or a comparison of two differentially processed products of the same gene that differ between normal and diseased subjects, or between different stages of the same disease. Differential expression encompasses both quantitative and qualitative differences in the temporal or cellular expression patterns of a gene or its expression product, for example, between normal and diseased cells, or between cells that have undergone different disease events or stages.

[0074] A "control level" of a target molecule refers to the level of the target molecule in properly treated samples of the same sample type. A control level may refer to the average level of the target molecule in properly treated samples from a population of individuals.

[0075] As used herein, "individual" refers to a test subject or patient. An individual can be a mammal or a non-mammal. In various embodiments, the individual is a mammal. A mammalian individual can be a human or a non-human. In various embodiments, the individual is a human. A healthy or normal individual is an individual in whom the disease or condition of interest (including, for example, dementia) is not detected by conventional diagnostic methods. A middle-aged individual is an individual aged 49 or older.

[0076] "Diagnosing," "diagnosing," "diagnosis," and variations thereof refer to detecting, determining, or distinguishing an individual's health state or condition based on one or more signs, symptoms, data, or other information about the individual. An individual's health state may be diagnosed as healthy / normal (i.e., a diagnosis of the absence of a disease or condition) or as diseased / abnormal (i.e., a diagnosis of the presence of a disease or condition, or an assessment of the characteristics of a disease or condition). The terms "diagnosing," "diagnosing," "diagnosis," and the like, with respect to a particular disease or condition, encompass the early detection of the disease; characterization or classification of the disease; detection of the progression, remission, or recurrence of the disease; and detection of disease response after administering treatment or therapy to an individual. Predicting dementia risk includes distinguishing between individuals at high risk of dementia and those who do not.

[0077] "Prognose," "prognosing," "prognosis," and variations thereof, refer to predicting the future course of a disease or condition (e.g., predicting patient survival) in an individual who has the disease or condition, and such terms encompass assessing the response of the disease or condition after administering treatment or therapy to the individual.

[0078] "Assess," "evaluating," "assessing," and variations thereof encompass both "diagnosis" and "prognosis," and also encompass the determination or prediction of the future course of a disease or condition in individuals who do not have the disease, and the determination or prediction of the risk of recurrence of the disease or condition in individuals who have apparently been cured of the disease or remission of the condition. The term "assessing" also encompasses assessing an individual's response to treatment, e.g., predicting whether an individual is likely to respond well to a therapeutic agent or unlikely to respond to a therapeutic agent (or, for example, whether they will experience toxic or other undesirable side effects), selecting a therapeutic agent to administer to an individual, or monitoring or determining an individual's response to a treatment administered to the individual. Thus, "assessing" dementia risk can include, for example, any of the following: predicting the future dementia risk in an individual; predicting dementia risk in an individual who does not have an apparent dementia problem. Assessing dementia risk can include embodiments such as assessing dementia risk on a continuous scale, or classifying dementia risk in ascending categories. Classification of risk includes, for example, classification into two or more categories, such as "no high risk of dementia" and "high risk of dementia." Assessment of dementia risk is for a predetermined time period, which can be, for example, 5, 10, 15, and / or 20 years. In some embodiments, assessment of dementia risk is for subjects aged 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 years or older.

[0079] As used herein, "additional biomedical information" refers to one or more assessments of an individual using other than any of the biomarkers described herein that are related to dementia risk. "Additional biomedical information" can include any of the following: an individual's physical descriptors, including the individual's height and / or weight; the individual's age; the individual's sex; weight change; the individual's ethnicity; occupational history; family history of dementia; the presence of genetic marker(s) correlated with a higher risk of dementia in an individual; clinical symptoms such as chest pain, weight gain or loss, gene expression values; an individual's physical descriptors, including physical descriptors observed by radiological imaging; smoking status; alcohol consumption history; occupational history; dietary habits, i.e., salt, saturated fat, and cholesterol intake; caffeine intake; and imaging information. Combining a biomarker level test with an assessment of any additional biomedical information, including other clinical tests, can improve the sensitivity, specificity, and / or AUC for predicting dementia, for example, compared to a biomarker test alone or an assessment of any specific item of additional biomedical information alone (e.g., carotid intima thickness imaging alone). The additional biomedical information may be obtained from the individual using routine techniques known in the art, such as from the individual themselves using routine patient or health history questionnaires, or from a healthcare professional, etc. Combining testing of biomarker levels with assessment of any additional biomedical information may improve the sensitivity, specificity, and / or threshold for predicting dementia, for example, compared to biomarker testing alone or assessment of any particular item of additional biomedical information alone (e.g., CT imaging alone).

[0080] As used herein, "detecting" or "determining" with respect to a biomarker value includes the use of both the equipment needed to observe and record a signal corresponding to the biomarker value as well as the substance or substances needed to generate that signal. In various embodiments, the biomarker value is detected using any suitable method, including fluorescence, chemiluminescence, surface plasmon resonance, surface acoustic waves, mass spectrometry, infrared spectroscopy, Raman spectroscopy, atomic force microscopy, scanning tunneling microscopy, electrochemical detection methods, nuclear magnetic resonance, quantum dots, etc.

[0081] As used herein, "solid support" refers to any substrate having a surface to which molecules can be directly or indirectly attached, either covalently or non-covalently. A "solid support" can have a variety of physical forms, including, for example, membranes; chips (e.g., protein chips); slides (e.g., glass slides or cover slips); columns; hollow, solid, semi-solid particles with pores or cavities, such as beads; gels; fibers, including fiber optic materials; matrices; and sample containers. Exemplary sample containers include sample wells, tubes, capillaries, vials, and any other container, groove, or depression capable of holding a sample. Sample containers can be included in multi-sample platforms, such as microtiter plates, glass slides, microfluidic devices, and the like. Supports can be composed of natural or synthetic materials, organic or inorganic materials. The composition of the solid support to which the capture reagent is attached generally depends on the method of attachment (e.g., covalent attachment). Other exemplary containers include microdroplets, microfluidically controlled, or bulk oil-in-water emulsions in which assays and related operations can be performed. Suitable solid supports include, for example, plastics, resins, polysaccharides, silica or silica-based materials, functionalized glass, modified silicon, carbon, metals, inorganic glass, membranes, nylon, natural fibers (e.g., silk, wool, and cotton), polymers, etc. The material comprising the solid support may contain reactive groups, such as carboxy, amino, or hydroxyl groups, which are used to attach capture reagents. Polymeric solid supports include, for example, polystyrene, polyethylene glycol tetraphthalate, polyvinyl acetate, polyvinyl chloride, polyvinylpyrrolidone, polyacrylonitrile, polymethyl methacrylate, polytetrafluoroethylene, butyl rubber, styrene-butadiene rubber, natural rubber, polyethylene, polypropylene, (poly)tetrafluoroethylene, (poly)vinylidene fluoride, polycarbonate, and polymethylpentene. Suitable solid support particles that can be used include, for example, coded particles, e.g., Luminex®-type coded particles, magnetic particles, and glass particles.

[0082] As used herein, an "analyte" is the protein target of a capture reagent. In certain embodiments, the capture reagent is an aptamer. In certain further embodiments, the capture reagent is a SOMAmer.

[0083] As used herein, "Lin's CCC" refers to the concordance correlation coefficient, which assesses the agreement between a new test and an existing test that is considered the gold standard.

[0084] As used herein, a "test" means a set of sample and clinical data that is analyzed to derive an assay.

[0085] As used herein, "training data set" means a subset of data from a test that is used to fit a model.

[0086] As used herein, "validation dataset" means the final subset of data used to evaluate the performance of the selected model developed in the validation dataset.

[0087] As used herein, a "validation dataset" means a distinct subset of data that provides an unbiased evaluation of a model fitted to a training dataset and is used to adjust the parameters of the model.

[0088] As used herein, the term "need" or "required" refers to a judgment made by a healthcare provider regarding treatment of a patient that is deemed by the healthcare provider to be beneficial to the patient's health status.

[0089] Risk Analysis In some embodiments, disclosed herein are objective tests for predicting dementia risk within 20 years. In some embodiments, disclosed herein are objective tests for predicting dementia risk within 15 years. In some embodiments, disclosed herein are objective tests for predicting dementia risk within 10 years. In some embodiments, disclosed herein are objective tests for predicting dementia risk within 5 years.

[0090] The risk analysis profile can be described as in Table 1. [Table 1-1] [Table 1-2]

[0091] The testing methods disclosed herein provide convenience to healthcare providers in assessing and monitoring dementia risk. [Table 2]

[0092] Performance goals were based on the performance of a major genetic risk variant for Alzheimer's disease (APOE ε4) in predicting future dementia risk (Escott-Price V, Sims R, Bannister C, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain. 2015;138(12):3673-3684).

[0093] Currently, there are no dementia risk prediction tests used as standard of care in routine clinical practice. Several clinical risk calculators have been developed to predict future dementia risk, such as the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score calculator (Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle-aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5(9):735-741). This risk calculator (and other similar risk calculators) rely on demographic, lifestyle, genetic, and clinical information that: 1) is immutable, limiting the feasibility of monitoring dementia risk over time; 2) relies on self-reported data; 3) has been poorly validated in independent cohorts; and 4) has not demonstrated a reproducible association with pathophysiological markers of current or future dementia etiology, such as Aβ deposition (Hooshmand B, Polvikoski T, Kivipelto M, et al. CAIDE Dementia Risk Score, Alzheimer and cerebrovascular pathology: a population-based autopsy study. J Intern Med. 2018;283(6):597-603; Stephen R, Liu Y, Ngandu T et al. Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition. J Alzheimers Dis. 2017;59(2):695-705). Several clinical risk calculators have been developed to predict near-term dementia risk, such as the Dementia Population Risk Tool (DemPoRT).Short-term risk calculators rely on similar factors as longer-term risk calculators. Other blood-based biomarker tests are being investigated for their ability to diagnose specific etiologies of Alzheimer's disease. For example, Diadem's Alzosure® has been granted Breakthrough Device Designation by the FDA and demonstrates the ability to predict the risk of Alzheimer's disease diagnosis within six years. However, currently, only APOE genotyping is generally accepted in clinical practice for assessing risk. Therefore, instead of comparing model performance with risk calculators not in clinical use, model performance was compared to the ability of risk alleles of the APOE gene to accurately predict who is at risk for future dementia.

[0094] The number of APOE ε4 risk alleles an individual possesses is the most commonly used genetic risk determinant for Alzheimer's disease, and this risk allele has also been associated with the risk of other dementia types, including cerebrovascular disease-related dementia and Lewy body disease (Tai LM, Thomas R, Marottoli FM, et al. The role of APOE in cerebrovascular dysfunction. Acta Neuropathol 2016;131(5):709-723). In 2017, the FDA approved the Late-Onset Alzheimer's Disease Genetic Health Risk report (US Food and Drug Administration. "FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions" [press release]. April 2017). The highest AUC demonstrated for APOE ε4 prediction of dementia risk is 0.678 (Escott-Price V, Sims R, Bannister C, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain. 2015;138(12):3673-3684). Therefore, an AUC of 0.678 or greater was used as the performance threshold for model development for midlife dementia risk testing. Furthermore, because a subset of participants in the ARIC study had known APOE genotype, direct intra-study comparisons of the proteomic model with the performance of the genetic model were possible.

[0095] In some embodiments, the number of biomarkers useful in a biomarker subset or panel is based on the sensitivity and specificity values for a particular combination of biomarker values. The terms "sensitivity" and "specificity" are used herein to refer to the ability to accurately classify individuals as having a high dementia risk within 20 years or not having a high dementia risk within the same period based on one or more biomarker values detected in a biological sample. "Sensitivity" refers to the performance of a biomarker(s) in accurately classifying individuals as having a high dementia risk. "Specificity" refers to the performance of a biomarker(s) in accurately classifying individuals as not having a high relative risk of dementia.

[0096] Alternatively, the score may be reported on a continuous range with thresholds of high, moderate, or low risk of dementia, the thresholds being determined based on clinical findings.

[0097] In some embodiments, the overall performance of a panel of one or more biomarkers is represented by an area under the curve (AUC) value. The AUC value is derived from a receiver operating characteristic (ROC) curve. An ROC curve plots the true positive rate (sensitivity) of a test against the false positive rate (1-specificity) of the test. The terms "area under the curve" or "AUC" refer to the area under a receiver operating characteristic (ROC) curve, both of which are well known in the art. AUC measurements are useful for comparing the accuracy of classifiers across a range of data. A classifier with a higher AUC is more capable of accurately classifying unknown individuals between two groups of interest (e.g., normal individuals and individuals at risk of dementia). ROC curves are useful for plotting the performance of a particular feature (e.g., any of the biomarkers described herein and / or any item of additional biomedical information) in distinguishing between two populations. Typically, feature data for an entire population is sorted in ascending order based on the value of a single feature. The true positive and false positive rates of the data are then calculated for each value of that feature. The true positive rate is determined by counting the number of cases that exceed the value for that feature and dividing by the total number of cases.The false positive rate is determined by counting the number of controls that exceed the value for that feature and dividing by the total number of controls.This definition refers to the case where the feature is high in cases compared to controls, but this definition also applies when the feature is lower in cases compared to controls (in such cases, samples that are below the value for that feature will be counted).ROC curves can be generated not only for single features but also for other single outputs.For example, a combination of two or more features can be mathematically combined (for example, by addition, subtraction, multiplication, etc.) to obtain a single total value, and this single total value can be plotted on an ROC curve.Furthermore, any combination of multiple features that leads to a single output value can be plotted on an ROC curve.

[0098] Exemplary Uses of Biomarkers In various exemplary embodiments, a method is provided for assessing the dementia risk of an individual by detecting one or more biomarker values corresponding to one or more biomarkers present in the circulation of an individual, for example, in blood, serum or plasma, by a number of analytical methods, including any of the analytical methods described herein.For example, these biomarkers are differentially expressed in individuals with high dementia risk compared with individuals without high dementia risk.Detecting the differential expression of biomarkers in individuals can be used, for example, to enable prediction of the dementia risk of middle-aged adults (49 years or older) within a 20-year period.

[0099] In addition to examining biomarker levels as a stand-alone diagnostic test, biomarker levels may be combined with measurements of SNPs or other genetic lesions or genetic variability that indicate increased susceptibility risk for a disease or condition (see, e.g., Amos et al., Nature Genetics 40, 616-622 (2009)).

[0100] Any of the described biomarkers may also be used in imaging studies, for example, an imaging agent may be combined with any of the described biomarkers, which may be used to aid in predicting dementia risk, to monitor response to therapeutic interventions, and to select target populations in clinical trials, among other uses.

[0101] Detection and Determination of Biomarkers and Biomarker Levels Biomarker levels of the biomarkers described herein can be detected using any of a variety of known analytical methods. In one embodiment, biomarker levels are detected using a capture reagent. As used herein, "capture agent" or "capture reagent" refers to a molecule that can specifically bind to a biomarker. In various embodiments, the capture reagent can be exposed to the biomarker in solution, or the capture reagent can be exposed to the biomarker while immobilized on a solid support. In other embodiments, the capture reagent has a feature that reacts with a second feature on the solid support. In these embodiments, the capture reagent can be exposed to the biomarker in solution, and then the feature on the capture reagent can be used in conjunction with the second feature on the solid support to immobilize the biomarker on the solid support. The capture reagent is selected based on the type of analysis to be performed. Capture reagents include, but are not limited to, SOMAmers, antibodies, adnectins, ankyrins, other antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small molecules, F(ab')2 fragments, single chain antibody fragments, Fv fragments, single chain Fv fragments, nucleic acids, lectins, ligand-binding receptors, affibodies, nanobodies, imprinted polymers, avimers, peptidomimetics, hormone receptors, cytokine receptors, and synthetic receptors, and modified versions and fragments thereof.

[0102] In some embodiments, biomarker levels are detected using a biomarker / capture reagent complex.

[0103] In other embodiments, the biomarker level is obtained from a biomarker / capture reagent complex and is detected indirectly, e.g., as a result of a reaction following biomarker / capture reagent interaction, but dependent on the formation of a biomarker / capture reagent complex.

[0104] In some embodiments, the biomarker level is detected directly from the biomarker in the biological sample.

[0105] In one embodiment, biomarkers are detected using a multiplexing format that allows for simultaneous detection of two or more biomarkers in a biological sample. In one embodiment of the multiplexing format, capture reagents are immobilized at separate locations on a solid support, either covalently or non-covalently, directly or indirectly. In another embodiment, the multiplexing format uses separate solid supports, where each solid support has a unique capture reagent bound to that solid support, e.g., quantum dots. In another embodiment, a separate device is used for detecting each of the multiple biomarkers to be detected in a biological sample. The separate device can be configured to allow each biomarker in a biological sample to be processed simultaneously. For example, a microtiter plate can be used, such that each well in the plate is used to uniquely analyze one of the multiple biomarkers to be detected in a biological sample.

[0106] In one or more of the foregoing embodiments, a component of the biomarker / capture reagent complex can be labeled using a fluorescent tag to enable detection of the biomarker value. In various embodiments, a fluorescent label can be conjugated to a capture reagent specific for any of the biomarkers described herein using known techniques, and the corresponding biomarker value can then be detected using the fluorescent label. Suitable fluorescent labels include rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives, dansyl, allophycocyanin, PBXL-3, Qdot 605, Lissamine, phycoerythrin, Texas Red, and other similar compounds.

[0107] In one embodiment, the fluorescent label is a fluorescent dye molecule. In some embodiments, the fluorescent dye molecule comprises at least one substituted indolium ring system in which a substituent on the carbon at the 3-position of the indolium ring contains a chemically reactive group or a conjugated substance. In some embodiments, the dye molecule includes an AlexFluor molecule, such as Alexafluor 488, Alexafluor 532, Alexafluor 647, Alexafluor 680, or Alexafluor 700. In other embodiments, the dye molecule comprises a first type of dye molecule and a second type of dye molecule, e.g., two different Alexafluor molecules. In other embodiments, the dye molecule comprises a first type of dye molecule and a second type of dye molecule, the two types of dye molecules having different emission spectra.

[0108] Fluorescence can be measured by a variety of instrumentation adaptable to a wide range of assay formats. For example, spectrofluorometers are designed to analyze microtiter plates, microscope slides, printed arrays, cuvettes, etc. See J.R. Lakowicz, Principles of Fluorescence Spectroscopy, Springer Science + Business Media, Inc., 2004. See Bioluminescence and Chemiluminescence: Progress Current Applications; Philip E. Stanley and Larry J. Kricka, editors, World Scientific Publishing Company, January 2002.

[0109] In one or more of the foregoing embodiments, a chemiluminescent tag may optionally be used to label a component of the biomarker / capture reagent complex to enable detection of the biomarker value. Suitable chemiluminescent substances include any of oxalyl chloride, rhodamine 6G, Ru(bipy)32+, TMAE (tetrakis(dimethylamino)ethylene), pyrogallol (1,2,3-trihydroxybenzene), lucigenin, peroxyoxalates, aryloxalates, acridinium esters, dioxetanes, and the like.

[0110] In yet other embodiments, the detection method involves an enzyme / substrate combination that generates a detectable signal corresponding to the biomarker value. Generally, the enzyme catalyzes a chemical change of a chromogenic substrate, which can be measured using a variety of techniques, including spectrophotometry, fluorescence, and chemiluminescence. Suitable enzymes include, for example, luciferase, luciferin, malate dehydrogenase, urease, horseradish peroxidase (HRPO), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, uricase, xanthine oxidase, lactoperoxidase, microperoxidase, and the like.

[0111] In yet other embodiments, the detection method may be a combination of fluorescent, chemiluminescent, radionuclide, or enzyme / substrate combinations that generate a measurable signal. Multimodal signal generation can be a unique and advantageous feature in biomarker assay formats.

[0112] More specifically, biomarker levels of the biomarkers described herein may be detected using known analytical methods, including singleplex SOMAmer assays, multiplex SOMAmer assays, singleplex or multiplex immunoassays, mRNA expression profiling, miRNA expression profiling, mass spectrometry, histological / cytological methods, etc., as described below.

[0113] Determining biomarker levels using aptamer-based assays Assays aimed at the detection and quantification of physiologically important molecules in biological and other samples are important tools in scientific research and healthcare. One class of such assays involves the use of microarrays containing one or more aptamers immobilized on a solid support. Each aptamer can bind to a target molecule in a highly specific manner and with extremely high affinity. See, e.g., U.S. Pat. No. 5,475,096, entitled "Nucleic Acid Ligands." See also, e.g., U.S. Pat. Nos. 6,242,246, 6,458,543, and 6,503,715, each entitled "Nucleic Acid Ligand Diagnostic Biochip." When the microarray is contacted with a sample, the aptamers bind to the respective target molecules present in the sample, thereby enabling the measurement of biomarker values corresponding to the biomarkers.

[0114] As used herein, "aptamer" refers to a nucleic acid that has specific binding affinity for a target molecule. It is recognized that affinity interaction is a matter of degree; however, in this context, the "specific binding affinity" of an aptamer to its target generally means that the aptamer binds to its target with a much higher degree of binding affinity than it binds to other components in the test sample. An "aptamer" is a set of copies of one type or species of nucleic acid molecule with a specific nucleotide sequence. An aptamer can contain any suitable number of nucleotides, including any number of chemically modified nucleotides. An "aptamer" refers to two or more sets of such molecules. Different aptamers can have either the same or different numbers of nucleotides. Aptamers can be DNA or RNA or chemically modified nucleic acids, and can be single-stranded, double-stranded, or contain double-stranded regions and higher-order structures. The aptamer may be a photoaptamer, which contains a photoreactive or chemically reactive functional group to allow the aptamer to be covalently linked to its corresponding target. Any of the aptamer methods disclosed herein may include the use of two or more aptamers that specifically bind to the same target molecule. As will be further described below, the aptamer may contain a tag. When an aptamer contains a tag, all copies of the aptamer do not need to have the same tag. Furthermore, when different aptamers each contain a tag, these different aptamers can have either the same tag or different tags.

[0115] Aptamers can be identified using any known method, including the SELEX process. Once identified, aptamers can be prepared or synthesized according to any known method, including chemical and enzymatic synthesis.

[0116] As used herein, "SOMAmer" or slow off-rate modified aptamer refers to an aptamer having improved off-rate characteristics. SOMAmers can be generated using the improved SELEX method described in U.S. Patent Application Publication No. 2009 / 0004667, entitled "Method for Generating Aptamers with Improved Off-Rates."

[0117] The terms "SELEX" and "SELEX process" are generally used interchangeably herein to refer to the combination of (1) the selection of aptamers that interact with a target molecule in a desired manner, e.g., bind to a protein with high affinity, and (2) the amplification of those selected nucleic acids. The SELEX process can be used to identify aptamers with high affinity for a specific target or biomarker.

[0118] SELEX generally involves preparing a mixture of candidate nucleic acids, binding the candidate mixture to a desired target molecule to form an affinity complex, separating the affinity complex from unbound candidate nucleic acids, separating and isolating the nucleic acids from the affinity complex, purifying the nucleic acids, and identifying a specific aptamer sequence. This process can be performed multiple times to further improve the affinity of the selected aptamer. This process can include an amplification step at one or more points in the process. See, for example, U.S. Patent No. 5,475,096, entitled "Nucleic Acid Ligands." The SELEX process can be used to generate aptamers that bind covalently to a target, as well as aptamers that bind non-covalently to a target. See, for example, U.S. Patent No. 5,705,337, entitled "Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-SELEX."

[0119] The SELEX process can be used to identify high-affinity aptamers containing modified nucleotides that confer improved properties to the aptamer, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and / or phosphate and / or base positions. Aptamers containing modified nucleotides identified by the SELEX process are described in U.S. Pat. No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," which describes oligonucleotides containing nucleotide derivatives chemically modified at the 5' and 2' positions of the pyrimidine. U.S. Pat. No. 5,580,737 (see above) describes highly specific aptamers containing one or more nucleotides modified with 2'-amino (2'-NH2), 2'-fluoro (2'-F), and / or 2'-O-methyl (2'-OMe). See also U.S. Patent Application Publication No. 20090098549, entitled "SELEX and PHOTOSELEX," which describes nucleic acid libraries with enhanced physical and chemical properties and their use in SELEX and photoSELEX.

[0120] SELEX can also be used to identify aptamers with desired off-rate characteristics. See U.S. Patent Application Publication No. 20090004667, entitled "Method for Generating Aptamers with Improved Off-Rates," which describes an improved SELEX process for generating aptamers capable of binding to target molecules. As mentioned above, these slow off-rate aptamers are known as "SOMAmers." A method for generating aptamers or SOMAmers and photoaptamers or photoSOMAmers with slower off-rates from their respective target molecules is described. The method includes contacting a candidate mixture with the target molecule, forming a nucleic acid-target complex, and performing a process to enrich for the slow off-rate aptamers, wherein the nucleic acid-target complexes with fast off-rates dissociate and do not reform, while the complexes with slow off-rates remain intact. Additionally, the method includes using modified nucleotides in the generation of candidate nucleic acid mixtures to create aptamers or SOMAmers with improved off-rate performance.

[0121] A variation of this assay uses aptamers containing photoreactive functional groups that allow the aptamer to covalently bind or be "photocrosslinked" to its target molecule. See, e.g., U.S. Pat. No. 6,544,776, entitled "Nucleic Acid Ligand Diagnostic Biochip." These photoreactive aptamers are also referred to as photoaptamers. See, e.g., U.S. Pat. Nos. 5,763,177, 6,001,577, and 6,291,184, entitled "Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX," respectively. See also, e.g., U.S. Pat. No. 6,458,539, entitled "Photoselection of Nucleic Acid Ligands." After the microarray is contacted with the sample and the photoaptamers have had an opportunity to bind to their target molecules, the photoaptamers are photoactivated and the solid support is washed to remove any non-specifically bound molecules. Because the covalent bond generated by the photoactivated functional group(s) on the photoaptamer typically does not remove the target molecules bound to the photoaptamer, stringent washing conditions can be used. In this way, the assay allows for the detection of biomarker values corresponding to the biomarkers in the test sample.

[0122] In both of these assay formats, the aptamer or SOMAmer is immobilized on a solid support before contacting with the sample. However, under certain circumstances, immobilizing the aptamer or SOMAmer before contacting with the sample may not provide an optimal assay. For example, pre-immobilization of the aptamer or SOMAmer may result in inefficient mixing of the aptamer or SOMAmer with the target molecule on the solid support surface, potentially prolonging the reaction time; therefore, extending the incubation time allows for efficient binding of the aptamer or SOMAmer to its target molecule. Furthermore, when a photoaptamer or photoSOMAmer is used in the assay, depending on the material utilized as the solid support, the solid support may tend to scatter or absorb the light used to achieve covalent bond formation between the photoaptamer or photoSOMAmer and its target molecule. Furthermore, depending on the method used, the surface of the solid support may be exposed to and affected by any labeling agent used, which may lead to inaccurate detection of the target molecule bound to the aptamer or photoSOMAmer. Finally, immobilization of an aptamer or SOMAmer on a solid support generally involves an aptamer or SOMAmer preparation step (i.e., immobilization) prior to exposure of the aptamer or SOMAmer to a sample, which preparation step may affect the activity or functionality of the aptamer or SOMAmer.

[0123] SOMAmer assays have also been described that allow a SOMAmer to capture its target in solution, followed by a separation step designed to remove certain components of the SOMAmer-target mixture prior to detection (see U.S. Patent Application Publication No. 20090042206, entitled "Multiplexed Analyses of Test Samples"). The described SOMAmer assay methods allow for the detection and quantification of non-nucleic acid targets (e.g., protein targets) in a test sample by detecting and quantifying nucleic acids (i.e., SOMAmers). The described methods create nucleic acid surrogates (i.e., SOMAmers) for detecting and quantifying non-nucleic acid targets, thereby allowing a wide variety of nucleic acid techniques, including amplification, to be applied to a wider range of desired targets, including protein targets.

[0124] SOMAmers can be constructed to facilitate separation of assay components from the SOMAmer-biomarker complex (or photoSOMAmer-biomarker covalent complex), allowing for isolation of the SOMAmer for detection and / or quantification. In some embodiments, these constructs can include cleavable or releasable elements within the SOMAmer sequence. In other embodiments, additional functionality can be introduced into the SOMAmer, such as a labeled or detectable component, a spacer component, or a specific binding tag or immobilization component. For example, a SOMAmer can include a tag or label linked to the SOMAmer via a cleavable moiety, and a spacer component separating the label and the cleavable moiety. In one embodiment, the cleavable element is a photocleavable linker. The photocleavable linker can be attached to a biotin moiety and a spacer moiety and can include an NHS group for amine derivatization, which can be used to introduce a biotin group into the aptamer, thereby allowing for release of the aptamer later in the assay.

[0125] Homogeneous assays, performed with all assay components in solution, do not require separation of the sample and reagents prior to signal detection. These methods are rapid and easy to use. These methods generate signals based on molecular capture or binding reagents that react with specific targets. In dementia prediction, the molecular capture reagent is an aptamer or antibody, and the specific target is a dementia biomarker, such as those in Table 6.

[0126] In some embodiments, the signal generation method utilizes the change in anisotropic signal resulting from the interaction of a fluorophore-labeled capture reagent with its specific biomarker target. When the labeled capture reagent reacts with its target, the increased molecular weight significantly slows the rotational motion of the fluorophore bound to the complex, resulting in a change in anisotropy. By monitoring the anisotropy change, the binding event can be used to quantitatively measure the biomarker in solution. Other methods include fluorescence polarization assays, molecular beacon techniques, time-resolved fluorescence quenching, chemiluminescence, and fluorescence resonance energy transfer.

[0127] An exemplary solution-based aptamer assay that can be used to detect a biomarker value corresponding to a biomarker in a biological sample includes: (a) preparing a mixture by contacting the biological sample with an aptamer that includes a first tag and has specific affinity for the biomarker, such that if the biomarker is present in the sample, an aptamer affinity complex is formed; (b) exposing the mixture to a first solid support that includes a first capture element, causing the first tag to associate with the first capture element; (c) removing any components of the mixture that are not associated with the first solid support; (d) removing a second tag from the mixture; (e) releasing the aptamer affinity complex from the first solid support; (f) exposing the released aptamer affinity complex to a second solid support comprising a second capture element, causing the second tag to associate with the second capture element; (g) removing any uncomplexed aptamer from the mixture by separating it from the aptamer affinity complex; (h) eluting the aptamer from the solid support; and (i) detecting the biomarker by detecting the aptamer component of the aptamer affinity complex.

[0128] Any means known in the art can be used to detect the aptamer component of an aptamer affinity complex and thereby detect biomarker values. Numerous different detection methods can be used to detect the aptamer component of an affinity complex, such as hybridization assays, mass spectrometry, or QPCR. In some embodiments, nucleic acid sequencing can be used to detect the aptamer component of an aptamer affinity complex and thereby detect biomarker values. In summary, a test sample can be subjected to any type of nucleic acid sequencing method to identify and quantify one or more aptamer sequences or sequences present in the test sample. In some embodiments, the sequence includes the entire aptamer molecule or any portion of the molecule that can be used to uniquely identify the molecule. In other embodiments, the identification sequence is a specific sequence added to the aptamer; such sequences are often referred to as "tags," "barcodes," or "zip codes." In some embodiments, the sequencing method includes an enzymatic step to amplify the aptamer sequence or to convert any type of nucleic acid, including RNA and DNA containing chemical modifications at any position, into any other type of nucleic acid suitable for sequencing.

[0129] In some embodiments, the sequencing method comprises one or more cloning steps, while in other embodiments, the sequencing method comprises direct sequencing without cloning.

[0130] In some embodiments, the sequencing method comprises a directed approach using specific primers that target one or more aptamers in the test sample, while in other embodiments, the sequencing method comprises a shotgun approach that targets all aptamers in the test sample.

[0131] In some embodiments, the sequencing method includes an enzymatic step to amplify the molecule targeted for sequencing. In other embodiments, the sequencing method directly sequences a single molecule. An exemplary nucleic acid sequencing-based method that can be used to detect biomarker values corresponding to biomarkers in a biological sample includes: (a) converting a mixture of aptamers containing chemically modified nucleotides into unmodified nucleic acids using an enzymatic step; (b) shotgun sequencing the resulting unmodified nucleic acids using a massively parallel sequencing platform, such as a 454 Sequencing System (454 Life Sciences / Roche), an Illumina Sequencing System (Illumina), an ABI SOLiD Sequencing System (Applied Biosystems), a HeliScope single molecule sequencer (Helicos Biosciences), or a Pacific BioSciences real-time single molecule sequencing system (Pacific BioSciences), or a Polonator G Sequencing System (Dover Systems); and (c) identifying and quantifying SOMAmers present in the mixture by specific sequences and sequence counts.

[0132] Determining biomarker values using immunoassays Immunoassays are based on the reaction of antibodies with their corresponding targets or analytes, and can detect analytes in samples depending on the specific assay format. To improve the specificity and sensitivity of immunoreactivity-based assay methods, monoclonal antibodies are frequently used due to their specific epitope recognition. Polyclonal antibodies have also been successfully used in various immunoassays due to their higher affinity for targets compared to monoclonal antibodies. Immunoassays are designed for use with a wide range of biological sample matrices. Immunoassay formats are designed to provide qualitative, semi-quantitative, and quantitative results.

[0133] Quantitative results are obtained by using a calibration curve prepared with known concentrations of the specific analyte to be detected. The response or signal from an unknown sample is plotted on the calibration curve, and the amount or value corresponding to the target in the unknown sample is determined.

[0134] Numerous immunoassay formats have been designed. ELISA or EIA can be quantitative for the detection of analytes. The method is based on the binding of a label to either the analyte or the antibody, and the label component includes an enzyme, either directly or indirectly. ELISA tests can be formatted for direct, indirect, competitive, or sandwich detection of analytes. Other methods are based on labels such as radioisotopes (I125) or fluorescence. Additional techniques include, for example, agglutination, nephelometry, turbidimetry, Western blot, immunoprecipitation, immunocytostaining, immunohistochemistry, flow cytometry, Luminex assay, etc. (See ImmunoAssay: A Practical Guide, edited by Brian Law, published by Taylor & Francis, Ltd., 2005).

[0135] Exemplary assay formats include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, fluorescence, chemiluminescence, and fluorescence resonance energy transfer (FRET) or time-resolved FRET (TR-FRET) immunoassays. Exemplary techniques for detecting biomarkers include biomarker immunoprecipitation followed by quantitative methods that allow size and peptide level differentiation, such as gel electrophoresis, capillary electrophoresis, planar electrochromatography, etc.

[0136] Methods for detecting and / or quantifying a detectable label or signal-producing substance depend on the nature of the label. The products of the reaction catalyzed by a suitable enzyme (where the detectable label is an enzyme; see above) can be, but are not limited to, fluorescent, luminescent, or radioactive, or they can absorb visible or ultraviolet light. Examples of detectors suitable for detecting such detectable labels include, but are not limited to, X-ray film, radioactivity counters, scintillation counters, spectrophotometers, colorimeters, fluorometers, luminometers, and densitometers.

[0137] Any of the detection methods can be performed in any format that allows for any suitable preparation, processing, and analysis of the reaction. The detection methods can be performed, for example, in multi-well assay plates (e.g., 96-well or 384-well) or using any suitable array or microarray. Stock solutions of various agents can be made manually or robotically, and all subsequent pipetting, dilution, mixing, dispensing, washing, incubation, sample reading, data collection, and analysis can be performed robotically using commercially available analysis software, robots, and detection equipment that can detect the detectable label.

[0138] Determining biomarker values using gene expression profiling Measuring mRNA in a biological sample can be used as a surrogate for detecting the level of the corresponding protein in the biological sample. Thus, any of the biomarkers or biomarker panels described herein can also be detected by detecting the appropriate RNA.

[0139] mRNA expression levels are measured by reverse transcription quantitative polymerase chain reaction (RT-PCR followed by qPCR). RT-PCR is used to generate cDNA from mRNA. The cDNA can be used in qPCR assays to generate fluorescence as the DNA amplification process progresses. qPCR can provide absolute measurements, such as the number of mRNA copies per cell, by comparison with a standard curve. Northern blots, microarrays, Invader assays, and RT-PCR combined with capillary electrophoresis have all been used to measure mRNA expression levels in samples. See Gene Expression Profiling: Methods and Protocols, Richard A. Shimkets, editor, Humana Press, 2004.

[0140] miRNA molecules are small, non-coding RNA molecules that can regulate gene expression. Any method suitable for measuring mRNA expression levels can also be used to measure the corresponding miRNA. In recent years, numerous laboratories have investigated the use of miRNAs as disease biomarkers. Because many diseases involve widespread transcriptional regulation, it is not surprising that miRNAs may find a role as biomarkers. While the relationship between miRNA concentrations and disease is often less clear than the relationship between protein levels and disease, miRNA biomarker value may be valuable. Naturally, as with any RNA that is differentially expressed during the course of a disease, challenges facing the development of in vitro diagnostic products include the requirement that miRNAs either persist in diseased cells and be easily extracted for analysis, or be released into blood or other matrices and persist there long enough for them to be measured. Protein biomarkers have similar requirements, but many protein biomarker candidates are intentionally secreted in a paracrine manner at sites of disease and function during the disease process. Many protein biomarker candidates are designed to function outside the cells in which the proteins are synthesized.

[0141] Biomarker detection using in vivo molecular imaging techniques Any of the described biomarkers (see Table 6) can also be used in molecular imaging studies. For example, an imaging agent can be combined with any of the described biomarkers, which can be used to help predict dementia risk, monitor response to therapeutic interventions, and select populations for clinical trials, among other uses.

[0142] In vivo imaging techniques provide a non-invasive method for determining the status of a particular disease or condition in an individual's body. For example, all parts of the body or the entire body can be displayed as a three-dimensional image, thereby providing useful information about the body's morphology and structure. Such techniques can be combined with the detection of biomarkers described herein to provide information about an individual's dementia status.

[0143] Various technological advances have led to the development of in vivo molecular imaging techniques. These advances include the development of new contrast agents or labels, such as radiolabels and / or fluorescent labels, that can generate strong signals within the body; and the development of powerful new imaging technologies that can detect and analyze these signals from outside the body with sufficient sensitivity and accuracy to provide useful information. The contrast agents can be visualized with an appropriate imaging system, thereby providing an image of the body part or parts in which the contrast agents are present. The contrast agents can be bound to or associated with, for example, capture agents such as aptamers or antibodies, and / or peptides or proteins or oligonucleotides (e.g., for detecting gene expression), or complexes containing any of these together with one or more macromolecules and / or other particulate forms.

[0144] Contrast agents may be characterized by radioactive atoms useful in imaging. Suitable radioactive atoms include technetium-99m or iodine-123 for scintigraphy. Other easily detectable moieties include spin labels for magnetic resonance imaging (MRI), such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron. Such labels are well known in the art and can be easily selected by those skilled in the art.

[0145] Standard imaging techniques include, but are not limited to, magnetic resonance imaging, computed tomography (coronary artery calcium score), positron emission tomography (PET), single-photon emission computed tomography (SPECT), computed tomography angiography, etc. In in vivo diagnostic imaging, the type of detection instrument available is an important factor in the selection of a given contrast agent, e.g., a given radionuclide and the specific biomarker (protein, mRNA, etc.) to be targeted using it. The radionuclide selected typically exhibits a certain type of decay that is detectable by a given type of instrument. In addition, when selecting a radionuclide for in vivo diagnosis, its half-life should be long enough to allow detection upon maximal uptake by the target tissue, and short enough to minimize harmful radiation to the host.

[0146] Exemplary imaging techniques include, but are not limited to, PET and SPECT, which are imaging techniques in which a radionuclide is administered systemically or locally to an individual. The subsequent uptake of the radioactive tracer is measured over time and used to obtain information about the targeted tissue and biomarker. Due to the high-energy (gamma-ray) emission of the specific isotopes used and the sensitivity and sophistication of the equipment used to detect it, the two-dimensional distribution of radioactivity can be estimated from outside the body.

[0147] Positron-emitting nuclides commonly used in PET include, for example, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. SPECT uses isotopes that decay by electron capture and / or gamma emission, including, for example, iodine-123 and technetium-99m. An exemplary method for labeling amino acids with technetium-99m is the reduction of pertechnetate ions in the presence of a chelating precursor to form an unstable technetium-99m-precursor complex, which then reacts with the metal-binding group of a bifunctionally modified chemotactic peptide to form a technetium-99m-chemotactic peptide conjugate.

[0148] Antibodies are frequently used in such in vivo imaging diagnostic methods. The preparation and use of antibodies for in vivo diagnosis is well known in the art. A labeled antibody that specifically binds to any of the biomarkers in Table 6 can be injected into an individual suspected of having an elevated dementia risk detectable by the particular biomarker used to diagnose or assess the individual's disease state or disease status. The label used is selected according to the imaging technique used, as described above. Localization of the label allows for the identification of tissue damage or other indicators related to dementia risk. The amount of label in an organ or tissue also allows for the identification of the involvement of a dementia biomarker based on dementia risk in that organ or tissue.

[0149] Similarly, aptamers may be used in such in vivo imaging diagnostic methods. For example, aptamers used to identify (and thus specifically bind to) specific biomarkers listed in Table 6 can be appropriately labeled and injected into individuals being evaluated for dementia detectable by specific biomarkers to diagnose or assess the levels of tissue damage, atherosclerotic plaques, components of the inflammatory response, and other factors associated with dementia risk in the individual. The label used is selected according to the imaging technique used, as described above. Localization of the label allows for identification of the site of a process that poses a high risk. The amount of label within an organ or tissue also allows for identification of the penetration of the pathological process into that organ or tissue. Aptamer-directed imaging agents may have unique and advantageous properties compared to other imaging agents in terms of tissue permeability, biodistribution, kinetics, clearance, efficacy, and selectivity.

[0150] Such techniques may optionally be carried out using labeled oligonucleotides to detect gene expression, for example, by imaging with antisense oligonucleotides. These methods are used, for example, in situ hybridization using fluorescent molecules or radionuclides as labels. Other methods for detecting gene expression include, for example, detecting the activity of reporter genes.

[0151] Another common type of imaging technique is optical imaging, in which fluorescent signals within a subject are detected by optical devices external to the subject. These signals can result from actual fluorescence and / or bioluminescence. Improvements in the sensitivity of optical detection devices have increased the usefulness of optical imaging for in vivo diagnostic assays.

[0152] The use of in vivo molecular biomarker imaging is increasing, for example, in clinical trials to more rapidly assess clinical efficacy, e.g., in testing new treatments for diseases or conditions, and / or to avoid long-term treatment with placebos in diseases such as multiple sclerosis, where such treatment may be considered ethically questionable.

[0153] For a review of other techniques, see N. Blow, Nature Methods, 6, 465-469, 2009.

[0154] Determining biomarker values using mass spectrometry Various configurations of mass spectrometers can be used to detect biomarker values. Several types of mass spectrometers are available or can be manufactured in various configurations. Generally, a mass spectrometer has the following main components: a sample inlet, an ion source, a mass analyzer, a detector, a vacuum system, an instrument control system, and a data system. The differences in the sample inlet, ion source, and mass analyzer generally define the type of instrument and its performance. For example, the inlet can be a capillary column liquid chromatography source, or a direct probe or stage such as used in matrix-assisted laser desorption. Common ion sources are electrospray, including nanospray and microspray, or matrix-assisted laser desorption. Common mass analyzers include quadrupole mass filters, ion trap mass analyzers, and time-of-flight mass analyzers. Additional mass spectrometry methods are well known in the art (see Burlingame et al., Anal. Chem. 70:647R-716R (1998); Kinter and Sherman, New York (2000)).

[0155] Protein biomarkers and biomarker levels can be detected and measured by any of the following: electrospray ionization mass spectrometry (ESI-MS), ESI-MS / MS, ESI-MS / (MS)n, matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF-MS), surface-enhanced laser desorption / ionization time-of-flight mass spectrometry (SELDI-TOF-MS), silicon-assisted desorption / ionization (DIOS), secondary ion mass spectrometry (SIMS), quadrupole time-of-flight (Q-TOF), a tandem time-of-flight (TOF / TOF) technology called UltraFlex III TOF / TOF, atmospheric pressure chemical ionization mass spectrometry (APCI-MS), APCI-MS / MS, APCI-(MS)n, atmospheric pressure photoionization mass spectrometry (APPI-MS), APPI-MS / MS, and APPI-(MS)n, quadrupole mass spectrometry, Fourier transform mass spectrometry (FTMS), quantitative mass spectrometry, and ion trap mass spectrometry.

[0156] Prior to characterizing protein biomarkers and determining biomarker values by mass spectrometry, sample preparation strategies are used to label and enrich samples. Labeling methods include, but are not limited to, iso-mass tagging for relative or absolute quantification (iTRAQ) and stable isotope labeling with amino acids in cell culture (SILAC). Capture reagents used to selectively enrich potential biomarker proteins in samples prior to mass spectrometry analysis include, but are not limited to, aptamers, antibodies, nucleic acid probes, chimeras, small molecules, F(ab')2 fragments, single-chain antibody fragments, Fv fragments, single-chain Fv fragments, nucleic acids, lectins, ligand-binding receptors, affibodies, nanobodies, ankyrins, domain antibodies, alternative antibody scaffolds (e.g., diabodies), imprinted polymers, avimers, peptidomimetics, peptoids, peptide nucleic acids, threose nucleic acids, hormone receptors, cytokine receptors, and synthetic receptors, as well as modified versions and fragments thereof.

[0157] Determination of biomarker values using proximity ligation assays Proximity ligation assays can be used to determine biomarker values. Briefly, a test sample is contacted with a pair of affinity probes, each of which can be a pair of antibodies or a pair of aptamers, with each member of the pair extended with an oligonucleotide. The targets of a pair of affinity probes can be two different determinants on a single protein, or one determinant each on two different proteins that can exist as a homo- or hetero-multimeric complex. When the probes bind to the target determinants, the free ends of the oligonucleotide extensions are brought into sufficient proximity to hybridize together. Hybridization of the oligonucleotide extensions is facilitated by a common connector oligonucleotide, which serves to bridge the oligonucleotide extensions together when they are positioned sufficiently close. Once the oligonucleotide extensions of the probes are hybridized, the ends of the extensions are linked together by enzymatic DNA ligation.

[0158] Each oligonucleotide extension contains a primer region for PCR amplification. When the oligonucleotide extensions are ligated together, the oligonucleotides form a continuous DNA sequence, which, through PCR amplification, reveals information about the identity and amount of the target protein, as well as information about protein-protein interactions if the target determinant exists on two different proteins. Proximity ligation can provide a highly sensitive and specific assay for real-time protein concentration and interaction information by using real-time PCR. Probes that do not bind to the determinant of interest will not bring the corresponding oligonucleotide extension into proximity, and ligation or PCR amplification cannot proceed, resulting in no signal generation.

[0159] The above-described assays allow for the detection of biomarker levels useful in methods for predicting dementia, wherein the method comprises detecting, in a biological sample from an individual, biomarker levels each corresponding to a biomarker selected from the group consisting of the biomarkers set forth in Table 6, wherein classification using the biomarker levels indicates whether a midlife individual has an elevated risk of developing dementia within a 5, 10, 15, and / or 20-year period, as described in detail below. While some of the described dementia biomarkers are useful alone for predicting dementia risk, methods are also described herein for grouping dementia biomarkers into subsets, each useful as a panel of two or more biomarkers. According to any of the methods described herein, biomarker levels can be detected and classified individually, or can be detected and classified together, such as in a multiplex assay format.

[0160] Biomarker classification and disease score calculation In some embodiments, the biomarker "signature" of a given diagnostic or predictive test comprises a set of markers, each of which exhibits different levels in a population of interest. In this context, different levels may refer to different average marker levels for individuals in two or more groups, or different variances in the two or more groups, or a combination of both. In the simplest form of a diagnostic test, these markers can be used to assign an unknown sample from an individual to one of two groups: one with or without a high dementia risk. Assigning a sample to one of two or more groups is known as classification, and the techniques used to achieve this assignment are known as classifiers or classification methods. Classification methods may also be referred to as scoring methods. There are many classification methods that can be used to construct a diagnostic classifier from a set of biomarker values. In general, classification methods are most easily performed using supervised learning techniques, in which a dataset is collected using samples obtained from individuals from two (or more in the case of multiple classification conditions) distinct groups to be distinguished. Because the class (group or population) to which each sample belongs is known in advance for each sample, a classifier can be trained to produce the desired classification response. Unsupervised learning techniques can also be used to generate diagnostic classifiers.

[0161] Common techniques for developing diagnostic classifiers include decision trees; bagging, boosting, forests, and random forests; rule-based learning; Parzen windows; linear models; logistic curves; neural network methods; unsupervised clustering; K-means; hierarchical ascending / descending classification; semi-supervised learning; prototype methods; nearest neighbor methods; kernel density estimation; support vector machines; hidden Markov models; and Boltzmann learning, and classifiers can be combined simply or in a way that minimizes a specific objective function. For a general discussion, see, e.g., *Pattern Classification*, *RODuda*, et al., editors, John Wiley & Sons, 2nd edition, 2001. See also *The Elements of Statistical Learning - Data Mining, Inference, and Prediction*, *T. Hastie*, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009 (each of which is incorporated by reference in its entirety).

[0162] To use supervised learning techniques to generate a classifier, a set of samples called training data is obtained.In the context of diagnostic testing, training data includes samples from different groups (classes) to which unknown samples are subsequently assigned.For example, the samples collected from individuals in a control group and individuals in a specific disease group, condition group, or event group can constitute the training data for developing a classifier that can classify unknown samples (or more specifically, the individuals from whom the samples are obtained) into either disease, condition, or high event risk, or no disease, condition, or high event risk.The development of a classifier from training data is known as classifier training. The specific details regarding training the classifier will depend on the nature of the supervised learning technique (see, e.g., Pattern Classification, R.O.Duda, et al., editors, John Wiley & Sons, 2nd edition, 2001; see also, The Elements of Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009).

[0163] Usually, there may be many higher biomarker values compared to the samples in training set, so care must be taken to avoid overfitting.Overfitting occurs when statistical model represents random error or noise instead of the underlying relationship.Overfitting can be avoided in various ways, including, for example, limiting the number of markers used in classifier development, assuming that the responses of markers are independent of each other, limiting the complexity of the underlying statistical model used, and ensuring that the underlying statistical model fits data.

[0164] To identify a set of biomarkers associated with the occurrence of an event, the combined set of control and early event samples was analyzed using principal component analysis (PCA). PCA presents samples along an axis defined by the greatest variation across all samples, regardless of case or control outcome, thereby reducing the risk of overfitting the distinction between cases and controls. Because the occurrence of a serious thrombotic event involves a strong chance component and requires the rupture of a vulnerable plaque within a critical vessel to be reported, a clear separation between the control and event sample sets is not expected. While the observed separation between cases and controls is modest, the second principal component accounts for approximately 10% of the total variation in this sample set, indicating that the underlying biological variation is relatively easy to quantify.

[0165] In the next analysis set, biomarkers can be analyzed for components of inter-sample differences that are specific to the separation between control samples and early event samples. One method that can be used is to use DSGA to remove (deflate) the top three principal component directions of variation between samples in the control set (Bair, E. and Tibshirani, R. (2004) Semi-supervised methods to predict patient survival from gene expression data. PLOS Biol., 2, 511-522). Dimensionality reduction is performed on the control set to be discovered, while both control samples and samples from early event samples are analyzed by PCA. Separation of cases from early event samples can be observed along the horizontal axis.

[0166] Cross-validation of selected proteins associated with dementia To avoid overfitting the predictive ability of proteins to the specific features of the selected samples, cross-validation and dimensionality reduction approaches can be employed. Cross-validation involves the combined selection of a sample set for determining the association of risk proteins with unselected samples, in conjunction with the use of unselected samples, to monitor the applicability of the methods of the present invention to samples not used to generate the risk model (The Elements of Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009). We applied the supervised PCA method of Tibshirani et al. (Bair, E. and Tibshirani, R. (2004) Semi-supervised methods to predict patient survival from gene expression data. PLOS Biol., 2, 511-522), which is applicable to high-dimensional datasets in dementia risk modeling. The supervised PCA (SPCA) method involves the univariate selection of a set of proteins that are statistically associated with the event risk observed in the data, and the determination of correlated components that combine information from all of these proteins. This correlated component determination is a dimensionality reduction step that not only combines information across proteins, but also mitigates the possibility of overfitting by reducing the number of independent variables from the entire protein menu of over 1000 proteins down to a few principal components (in this work, we considered only the first principal component).

[0167] Univariate and multivariate analyses of the relationship between individual proteins and time to events The Cox proportional hazards model (Cox, David R (1972). "Regression Models and Life-Tables." Journal of the Royal Statistical Society. Series B (Methodological) 34(2):187-220) is widely used in medical statistics. Cox regression avoids fitting a specific time function to cumulative survival rates and instead uses a model of relative risk, called the baseline hazard function, which can change over time. The baseline hazard function describes the shape of the survival time distribution common to all individuals, while the relative risk indicates the level of risk for a set of covariate values (e.g., a single individual or a group) as a multiple of the baseline hazard. In the Cox model, the relative risk is constant over time.

[0168] Accelerated mortality time (AFT) models are a subclass of survival models. Survival models predict time-to-event data based on partial information. For example, in the dementia model data, the event is a diagnosis of dementia, but the time-to-diagnosis event data is only available for some subjects in the study. For the remaining subjects, the available information is that they were not diagnosed with dementia between the time of blood collection and the end of the study. This second category is partial information, called "censored," because it is uncertain whether or when they will be diagnosed with dementia.

[0169] Because survival models account for censoring, they can also use data from censored subjects, whereas other longitudinal models that attempt to predict when an event will occur may only use information from subjects diagnosed with dementia. Also, because survival models consider time to event occurrence, they can provide predictions of the probability of an event occurring within any time frame, which differs from most classification models (logistic regression, random forests).

[0170] In particular, the AFT survival model is a regression model that specifies / assumes a linear relationship between the model covariates and log(time to event). Thus, a subject with a covariate (protein RFU counts) that is 2 times higher than baseline may be predicted to "escape" a dementia diagnosis for 2 times longer than baseline.

[0171] The two most common survival models are the AFT model and the proportional hazards model, and the AFT-Weibull model is both. The definition of the proportional hazards model is a little more complicated than that of the AFT model, in which a subject with a covariate that is twice as high as the baseline may have a twice as high risk at any time point, where the risk is the negative derivative of the survival curve over time.

[0172] Other common proportional hazards models are the exponential and Cox models. The exponential model is a special type of the Weibull model. The Cox model is of more limited use; it does not provide predicted probabilities of time to an event, only relative risks. The AFT model provides both absolute and relative risks.

[0173] kit For example, any combination of biomarkers in Table 6 can be detected using a suitable kit for use in practicing the methods disclosed herein. Additionally, any kit can include one or more detectable labels, such as fluorescent moieties, as described herein.

[0174] In some embodiments, the kit comprises: (a) one or more capture reagents (e.g., at least one aptamer or antibody) for detecting one or more biomarkers in a biological sample, the biomarkers including any of the biomarkers listed in Table 6; and, optionally, (b) one or more software or computer program products for classifying an individual from whom the biological sample was obtained as having or not having an elevated dementia risk, or for determining the likelihood that the individual has an elevated dementia risk, as further described herein. Alternatively, rather than one or more computer program products, one or more instructions for a person to manually perform the above steps may be provided.

[0175] The combination of a solid support and a corresponding capture reagent with a signal-generating agent is referred to herein as a "detection device" or "kit." The kit may also include instructions for use of the device and reagents, sample handling, and data analysis. Additionally, the kit may be used with a computer system or software for analyzing biological samples and reporting the results of the analysis.

[0176] The kits may also include one or more reagents for processing the biological sample (e.g., solubilization buffer, detergent, wash solution, or buffer). Any of the kits described herein may also include, for example, buffers, blocking agents, mass spectrometry matrix materials, antibody capture agents, positive control samples, negative control samples, software, and information, such as protocols, guidelines, and reference data.

[0177] In one aspect, the present invention provides a kit for analyzing dementia risk status. The kit includes PCR primers for one or more aptamers specific to a biomarker selected from Table 6. The kit may further include instructions for use and instructions regarding the relationship between the biomarkers and the prediction of dementia risk. The kit may also include a DNA array containing complements of one or more aptamers specific to a biomarker selected from Table 6, reagents, and / or enzymes for amplifying or isolating sample DNA. The kit may include reagents for real-time PCR, such as TaqMan probes and / or primers, and enzymes.

[0178] For example, a kit may include (a) reagents including at least a capture reagent for quantifying one or more biomarkers in a test sample, wherein the biomarkers include the biomarkers listed in Table 6 or any other biomarker or biomarker panel described herein, and optionally (b) one or more algorithms or computer programs for performing the steps of comparing the amount of each quantified biomarker in the test sample to one or more predetermined cutoff values and assigning a score for each quantified biomarker based on the comparison, adding the assigned scores for each quantified biomarker to obtain a total score, comparing the total score to a predetermined score, and using the comparison to determine whether an individual has an elevated dementia risk. Alternatively, rather than one or more algorithms or computer programs, one or more instructions for a person to manually perform the above steps may be provided.

[0179] Computer Methods and Software Once a biomarker or panel of biomarkers has been selected, a method for diagnosing an individual can include: 1) collecting or otherwise obtaining a biological sample; 2) performing an analytical method to detect and measure the panel biomarker or biomarkers in the biological sample; 3) performing any data normalization or standardization required by the method used to collect biomarker levels; 4) calculating a marker score; 5) adding the marker scores together to obtain a total diagnostic or predictive score; and 6) reporting the individual's diagnostic or predictive score. In this approach, the diagnostic or predictive score can be a single number determined by summing all marker calculations, which is compared to a preset threshold that indicates the presence or absence of disease. Alternatively, the diagnostic or predictive score can be a series of bars, each representing a biomarker level, and the response pattern can be compared to a preset pattern to determine the presence or absence of elevated (or non-elevated) risk of a disease, condition, or event.

[0180] At least some embodiments of the methods described herein may be implemented using a computer. FIG. 4 illustrates an example computer system 100. Referring to FIG. 4, system 100 is shown to be comprised of hardware elements electrically connected via bus 108, including processor 101, input device 102, output device 103, storage device 104, computer-readable storage medium reader 105a, communication system 106, accelerated processing unit (e.g., DSP or special-purpose processor) 107, and memory 109. Computer-readable storage medium reader 105a is further connected to computer-readable storage medium 105b, which collectively represents storage media, memory, and the like, in addition to remote, local, fixed, and / or removable storage devices, for temporarily and / or more persistently containing computer-readable information, and which includes storage device 104, memory 109, and / or any other such accessible system 100 resources. System 100 also includes software elements (shown here as residing in working memory 191) that include an operating system 192 and other code 193, eg, programs, data, etc.

[0181] Referring to FIG. 4 , system 100 has a wide range of flexibility and configurability. Thus, for example, a single architecture may be utilized to implement one or more servers, which may further be configured according to generally desired protocols, protocol modifications, extensions, and the like. However, it will be apparent to those skilled in the art that embodiments may be utilized according to more specific application requirements. For example, one or more system elements may be implemented as sub-elements within a component of system 100 (e.g., within communications system 106). Customized hardware may be utilized, and / or particular elements may be implemented in hardware, software, or both. Additionally, connections to other computing devices, such as network input / output devices (not shown), may be utilized, although it should be understood that wired, wireless, modem, and / or other connections or multiple connections to other computing devices may also be utilized.

[0182] In one embodiment, the system may include a database containing biomarker features that indicate predictive characteristics of dementia risk. Biomarker data (or biomarker information) may be utilized as input to a computer for use as part of a computer-implemented method. Biomarker data may include data described herein.

[0183] In one aspect, the system further includes one or more devices for providing input data to the one or more processors.

[0184] The system further includes a memory for storing the dataset of ranked data elements.

[0185] In another embodiment, the device for providing input data includes a detector for detecting characteristics of the data elements, such as, for example, a mass spectrometer or a gene chip reader.

[0186] The system may additionally include a database management system. User requests or queries may be formatted in an appropriate language understood by the database management system, which processes the queries and extracts relevant information from a database of training sets.

[0187] The system may be connectable to a network to which a network server and one or more clients are connected. The network may be a local area network (LAN) or a wide area network (WAN), as is well known in the art. Preferably, the server includes the hardware necessary to execute a computer program product (e.g., software) for accessing data from a database to process user requests.

[0188] The system may include an operating system (e.g., UNIX or Linux) for executing instructions from a database management system. In one aspect, the operating system may operate over a global communications network, such as the Internet, and may utilize a global communications network server for connecting to such a network.

[0189] The system may include one or more devices that include a graphical display interface, including interface elements such as buttons, pull-down menus, scroll bars, text entry fields, etc., commonly found in graphical user interfaces known in the art. Requests entered at the user interface may be transmitted to application programs in the system for formatting to search for relevant information in one or more system databases. Requests or queries entered by users may be formulated in any suitable database language.

[0190] A graphical user interface may be generated by graphical user interface code as part of the operating system and may be used to input data and / or display input data. The results of processed data may be displayed on the interface, printed on a printer in communication with the system, saved to a storage device, and / or transmitted over a network, or provided in the form of a computer-readable medium.

[0191] The system may be in communication with an input device for providing data (e.g., expression values) regarding the data elements to the system. In one aspect, the input device may include a gene expression profiling system, including, for example, a mass spectrometer, a gene chip, or an array reader.

[0192] According to various embodiments, the method and device for analyzing dementia risk predictive biomarker information can be implemented in any suitable manner, for example, using a computer program running on a computer system.A conventional computer system including a processor and random access memory can be used, such as a remotely accessible application server, a network server, a personal computer, or a workstation.Additional computer system elements can include a storage device or information storage system, for example, a mass storage system, and a user interface, for example, a conventional monitor, keyboard, and tracking device.The computer system can be a stand-alone system or part of a network of computers, including a server and one or more databases.

[0193] The dementia risk predictive biomarker analysis system may provide functions and operations for completing data analysis, such as data collection, processing, analysis, reporting, and / or diagnosis. For example, in one embodiment, a computer system may execute a computer program that may receive, store, retrieve, analyze, and report information about dementia risk predictive biomarkers. The computer program may include multiple modules that perform various functions or operations, such as a processing module for processing raw data and generating supplemental data, and an analysis module for analyzing the raw data and supplemental data to generate a predicted dementia risk status and / or diagnosis or risk calculation. Calculating a dementia risk status may optionally include generating or retrieving any other information, including additional biomedical information regarding the individual's status related to a disease, condition, or event, identifying whether further testing may be desirable, or otherwise assessing the individual's health status.

[0194] Referring now to FIG. 5, an example of a computer-implemented method according to the principles of the disclosed embodiments can be seen. FIG. 5 illustrates a flowchart 3000. At block 3004, biomarker information for an individual can be retrieved. The biomarker information can be retrieved, for example, from a computer database after testing of the individual's biological sample has been performed. The biomarker information can include biomarker levels, each corresponding to one or more of the biomarkers in Table 6. At block 3008, a computer can be utilized to classify each biomarker level. Furthermore, at block 3012, a determination can be made based on the plurality of classifications as to the likelihood that the individual has an elevated dementia risk. The representation can be output to a display or other display device for human viewing. Thus, for example, it can be displayed on a computer display screen or other output device.

[0195] Some embodiments described herein may be implemented to include a computer program product, which may include a computer-readable medium having computer-readable program code embodied in the medium for causing an application program to be executed on a computer having a database.

[0196] As used herein, a "computer program product" refers to a set of instructions, organized in the form of natural or programming language statements, contained on a physical medium of any nature (e.g., written, electronic, magnetic, optical, or otherwise) and usable by a computer or other automatic data processing system. Such programming language statements, when executed by a computer or data processing system, cause the computer or data processing system to operate in accordance with the specific content of the statements. Computer program products include, but are not limited to, programs in source and object code and / or test or data libraries stored on a computer-readable medium. Furthermore, computer program products that enable a computer system or data processing device to operate in a preselected manner may be provided in numerous forms, including, but not limited to, original source code, assembly code, object code, machine language, encrypted or compressed versions of the foregoing, and any equivalents.

[0197] In one aspect, a computer program product for assessing dementia risk is provided, the computer program product including a computer-readable medium having program code embodied thereon executable by a processor of a computing device or system, the program code including: code for retrieving data resulting from biological samples from individuals, the data including biomarker values each corresponding to one or more of the biomarkers in Table 6; and code for implementing a classification method that indicates the dementia risk status of the individual as a function of the biomarker values.

[0198] In yet another aspect, a computer program product for indicating a probable dementia risk is provided, the computer program product including a computer-readable medium having program code embodied thereon executable by a processor of a computing device or system, the program code including: code for retrieving data from a biological sample from an individual, the data including biomarker values corresponding to one or more of the biomarkers in Table 6; and code for implementing a classification method to indicate the dementia risk status of the individual as a function of the biomarker values.

[0199] While various embodiments have been described as methods or apparatus, it should be understood that the embodiments may be implemented via code in conjunction with a computer, e.g., code resident on or accessible by a computer. For example, software and databases may be utilized to implement many of the above-described methods. Thus, in addition to embodiments achieved through hardware, it should also be noted that these embodiments may be achieved through the use of an article of manufacture comprising a computer-usable medium having computer-readable program code embodied thereon that enables the performance of the functions disclosed herein. Accordingly, it is desirable that the embodiments be considered equally protected by this patent in their program code form. Furthermore, the embodiments may be embodied as code stored in virtually any type of computer-readable memory, including, but not limited to, RAM, ROM, magnetic, optical, or magneto-optical media. Even more generally, the embodiments may be implemented in software, including, but not limited to, software running on a general-purpose processor, microcode, PLA, or ASIC, or in any combination thereof.

[0200] It is further contemplated that embodiments may be achieved as computer signals embodied in carrier waves and signals propagated over transmission media (e.g., electrical and optical). Thus, the various types of information described above may be formatted in structures, such as data structures, and transmitted as electrical signals over transmission media or stored on computer-readable media.

[0201] It should also be noted that many of the structures, materials, and acts recited herein may be recited as a means for performing a function or a step for performing a function, and therefore, such language should be understood to encompass all such structures, materials, or acts disclosed within this specification, including material incorporated by reference, and their equivalents.

[0202] The biomarker identification process, uses of the biomarkers disclosed herein, and various methods for determining biomarker values are described in detail with respect to assessing dementia risk, however, the application of the process, uses of the identified biomarkers, and methods for determining biomarker values are fully applicable to identifying other specific types of diseases or medical conditions, or individuals who may or may not benefit from adjunctive medical treatment. [Example]

[0203] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the present application, which is defined by the appended claims. All examples described herein were carried out using standard techniques that are well known and routine to those skilled in the art. The routine molecular biology techniques described in the following examples can be carried out as described in standard laboratory manuals, such as Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (2001).

[0204] Example 1: Multiplexed aptamer assay and statistical approach for biomarker identification A multiplex aptamer assay was used to analyze test samples and control samples to identify biomarkers that predict dementia risk within 20 years.The multiplex analysis used in this experiment included aptamers for detecting approximately 5,000 proteins in blood from a small sample volume (approximately 65 μl of serum or plasma) with a low detection limit (median 1 pM), a dynamic range of approximately 7 logs, and a median coefficient of variation of approximately 5%.Multiplex aptamer assays are generally described, for example, in Gold et al.(2010) Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery.PLoS ONE 5(12):e15004; and US Patent Application Publication Nos. 2012 / 0101002 and 2012 / 0077695.

[0205] Example 2: Model specifications The endpoint for these analyses was the time-to-onset dementia outcome, which has two components: 1) the time in days from blood draw to diagnosis of dementia (by Level 3 adjudication methods including cognitive assessment testing, telephone screening, informant assessment, hospital records, and death record review) or study discontinuation / completion, and 2) a binary variable indicating whether a Level 3 dementia diagnosis was observed during the study period.

[0206] The model selected was an accelerated death time (AFT) model using a Weibull distribution with only 25 protein features (see Table 6). The model was trained throughout the entire study period, with performance peaking at 20 years. Table 3 shows the performance metrics of the model.

[0207] [Table 3]

[0208] The model provides two predictions:

[0209] 1) Absolute Risk: This output is the absolute probability of not being diagnosed with dementia within 20 years (traditional Pr(No Dementia), value between 0 and 1). When submitted as a result and evaluated by business rules, the resulting predicted probability is subtracted from 1 to obtain the 20-year absolute probability of being diagnosed with dementia.

[0210] 2) Relative Risk: This is a continuous variable calculated using the absolute risk probability generated by the model (above) divided by the "baseline" absolute probability (defined below) in the training cohort. This approach allows the model's risk probability predictions to be interpreted such that higher values indicate a higher likelihood of being diagnosed with dementia within the next 20 years.

[0211] The baseline risk probability score represents the absolute risk for the "average" person in the training cohort based on the model algorithm. A "baseline" individual is defined as an individual with model feature values set to zero. All features in the model are globally mean-centered, meaning that for any given feature value, a value of 0 is equal to the mean (i.e., average). The baseline value is calculated by setting all features to zero and then generating an absolute risk probability for those "zeroed" features. Thus, a score less than 1 represents a lower than average risk, and a score greater than 1 represents a higher than average risk. The 20-year dementia diagnosis rate in the ARIC dataset is consistent with the dementia event rate of the US population of the same age as the intended use population.

[0212] The baseline absolute risk score in the training data is 0.15 or 15%.

[0213] Relative risk scores (where relative risk is the absolute risk divided by the baseline absolute risk of 0.15) and absolute risk scores were stratified into four clinically meaningful risk categories in the training dataset. Kaplan-Meier (KM) plots spanning the entire study period (30 years) were generated for these risk bins in the training and validation datasets. Note that the first two risk bins (low and intermediate-low) correspond to individuals with a predicted risk of dementia diagnosis lower than the average risk based on our data (baseline score of 0.15, relative risk of 1 or less), while the intermediate-high and high risk bins correspond to predicted risks higher than the mean / baseline.

[0214] A summary of the absolute and relative risk stratification and corresponding event rates is shown in Table 4. Both unadjusted and KM event rates are shown, with the KM event rate taking into account censoring. [Table 4] Based on this stratification, the scoring rules for absolute and relative risks in the midlife dementia risk test are shown in Table 5. [Table 5] To assess the calibration of the midlife dementia risk screening model, we generated KM plots comparing the KM estimates of observed event rates stratified by risk deciles with the predicted probabilities of selected models (Figure 2). Note that the error bars generally lie near the 45-degree line, indicating that the mean predicted probabilities from the model accurately represent the event rates observed in the training data and that the model is well calibrated. [Table 6-1] [Table 6-2]

[0215] The output of the model is Pr(dementia free) at 20 years. The output is reported as the probability of being diagnosed with dementia, which is (1-Pr(dementia free)). The 20-year event probability is reported as a continuous variable. Because the output of this model is a probability, values outside the range [0,1] are malfunctions and will not be reported. [Table 7]

[0216] Example of LDT usage: A hypothetical patient has a predicted absolute probability equal to 0.76 based on a proteomic model. The relative risk for this patient is 5.07, placing the patient in the high-risk bin. This relative risk in this example is interpreted as follows: this patient has a 5.07-fold or 407% increased risk of being diagnosed with dementia within the next 20 years compared to the average individual in our reference population.

number

[0217] Example 3: Dataset for test development and validation Development and Validation Cohort(s). The Atherosclerosis Risk in Communities (ARIC) study is a prospective epidemiological study conducted in four communities in the United States: Forsyth County, NC; Jackson, MS; the northwest suburbs of Minneapolis, MN; and Washington County, MD. The ARIC study enrolled 15,792 participants aged 45–64 years. Enrollment occurred between 1987 and 1989, and follow-up is currently ongoing for 30 years, with study visit 7 in 2018–2019. The ARIC study was originally designed to investigate the etiology and natural history of atherosclerosis, the pathogenesis of clinical atherosclerotic disease, and differences in cardiovascular risk factors, medical care, and disease by race, sex, location, and date. However, expansions were undertaken to facilitate epidemiological studies of dementia. Dementia diagnoses (including Alzheimer's disease, cerebrovascular disease-related dementia, Lewy body-related dementia, or undefined dementia) were determined through cognitive assessment tests, telephone screening, informant assessment, hospital records, and death record review. A midlife dementia risk model was developed based on documented dementia diagnoses (Level 3 assessments) beginning with the third visit performed between 1993 and 1995 through a 30-year follow-up period; however, the model is intended to function for dementia diagnoses up to 20 years of follow-up (Knopman DS, et al. Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst). 2016;2:1-11).

[0218] Recent estimates suggest that the prevalence of Alzheimer's disease dementia is approximately 13.8% among people aged 75 to 84. The mean absolute probability of developing dementia within the 20-year period from Visit 3 (mean age 60 years) to Visit 6 (mean age 79 years) in this dataset was 0.15 or 15%, thus consistent within the range of US prevalence estimates.

[0219] Dataset stratification. In this study, data were split into three independent sets (70% training / 15% validation / 15%) and stratified by dementia diagnosis as the endpoint as described by Escott-Price et al., which allowed for the identification of robust models while mitigating overfitting issues (Escott-Price V, et al. Brain. 2015;138(12):3673-3684). The validation dataset was not used in the POC or refinement phases.

[0220] Model development data [Table 8] [Table 9]

[0221] Model Validation Data [Table 10] [Table 11]

[0222] Model Validation Data [Table 12] [Table 13]

[0223] Example 4: Development Results Data QC and Pre-Analysis Results. The original clinical dataset contained 11,361 samples. The following number of samples were removed based on various flags. This removal is detailed in Table 10. [Table 14]

[0224] Additionally, 363 analytes failed the target confirmation specificity test and were removed prior to the start of the analysis, leaving 4921 analytes available for analysis. No other issues were identified during data QC or pre-analysis. Samples in this study were analyzed with the analyte assay from May 13, 2019, to July 8, 2019.

[0225] POC approach and results: Model performance requirements were met, with an AUC of 0.678 or greater over 20 years.

[0226] Improved approach and results.

[0227] The model selected for the midlife dementia risk test was a 25-analyte AFT survival model using a Weibull distribution. The model was trained on the ARIC Visit 3 dataset, which included 70% of those without pre-existing dementia. Validation metrics were calculated on a split 15% dataset, with an additional 15% dataset held out for use in validation. The primary model output was absolute risk (%) (i.e., probability of an event (level 3 dementia diagnosis)) within 20 years of blood draw.

[0228] Observations throughout the study period were used to optimize model performance at 20 years. Analytes were selected for model selection through a series of feature filtering and feature reduction methods. Feature selection was performed primarily using the Cox proportional hazards elastic net model, which required the proportionality assumption to be met, and therefore an FDR of 0.05 or less in the proportional hazards test was used as the criterion for removing analytes. 16 Analytes for which there was evidence of violation of the proportional hazards assumption were removed by initial feature filtering using the .

[0229] Additionally, features showing low concordance (Lin's CCC<0.85) between the V4 validation data and the refined V4.1 BioIVT validation data were excluded from model development. An important requirement for the selected model was that it performed well on both the V4 and V4.1 SomaScan data. Although the ARIC SomaScan data are from the V4 version, in our application, the test is performed on the V4.1 data. To develop a model that performed well on both, only analytes showing higher concordance were used for refinement.

[0230] After removing the above analytes, the top 50 analytes ranked by univariate testing were then selected for model development, and cross-validation was performed to confirm that the features contained sufficient signal to effectively predict dementia outcomes. The feature set was reduced to 25 (out of the initial 50 features) using a single Cox-LASSO run, followed by 10-fold cross-validation using an elastic net Cox PH model. These results showed that the model with ridge penalization performed best, suggesting that further reduction of the feature space resulted in poorer predictive performance.

[0231] Both the Weibull AFT model and the elastic net Cox PH model using the 25 features selected in the above procedure were evaluated for robustness using our model evaluation tool. Although both models performed comparably in terms of predictive performance (i.e., AUC), the Weibull AFT model passed the validation criteria from V4.0 to V4.1, while the Cox model did not. The Weibull model was selected as the model of choice.

[0232] The performance metrics for the training and validation data evaluated at 20 years are shown in Table 11. The AUC values for training and validation meet the requirement of an AUC of 0.678 or greater. The lower limit of the confidence interval for the AUC in the validation data is also greater than 0.678, suggesting that our results are robust. Although the AUC in the validation dataset is slightly higher than the AUC in the training data, the difference is minor, not significant, and falls within the 95% confidence interval. [Table 15]

[0233] Performance at 5, 10, and 15 years. Selected models were further used to predict the risk of dementia diagnosis in midlife 5, 10, and 15 years after blood draw, and performance metrics were calculated. The performance metrics are detailed in Table 12. [Table 16]

[0234] Performance at Default Sensitivity Thresholds. The performance of selected models at default sensitivity thresholds (0.8, 0.90, and 0.95) was evaluated on the training and validation datasets, as shown in Table 13. Table 13: Performance metrics of the model at 20 years at sensitivity levels of 0.8, 0.9, and 0.95. The AUC on the training data is 0.732 and the AUC on the validation data is 0.733. [Table 17]

[0235] Performance compared to APOE. The performance of the selected models was compared to the predictive performance of APOE genotypes in predicting dementia risk in individuals. The following assessments were performed: 1. Using the selected model fitted to the training data, evaluate model performance on the subset of training samples with APOE genotype information (APOE-only data). 2. Evaluate model performance on APOE-only data using selected models fitted to APOE-only data. 3. Fit the model to the APOE-only data using selected model features, including APOE as a covariate, and evaluate model performance on the APOE-only data. 4. Using a model with only APOE as a covariate, fit the model to the APOE-only data and evaluate model performance on the APOE-only data. APOE genotyping for the ε2, ε3, and ε4 alleles was performed only in a subset of ARIC participants, so model performance can be performed on a subset of samples.

[0236] Forty-four percent of individuals in the ARIC Visit 3 dataset were assigned an APOE genotype (represented by three allele combinations: ε2, ε3, and ε4). Homozygotes for the ε2 allele were rare, and only two samples with this genotype were diagnosed with dementia within the past 20 years. Therefore, samples with E2 / E2 and E2 / E3 genotypes were collapsed into a single category. The resulting five-level factor was added as a feature to the model selected for our model comparison. The distribution of APOE allele combinations in the training and validation datasets, split by dementia diagnosis status, is shown in Tables 14 and 15, respectively. [Table 18] [Table 19]

[0237] The demographics of individuals with known and unknown APOE genotypes in the training and validation datasets, stratified by dementia diagnostic status, are shown in Tables 16 and 17, respectively.

[0238] [Table 20-1] [Table 20-2]

[0239] [Table 21-1] [Table 21-2]

[0240] Model performance metrics for models fitted with and without APOE genotypes are shown in Table 18. The final proteomic model outperformed the model consisting of APOE genotypes alone (AUC of 0.718 vs. 0.609). On the training data, the final model including APOE genotypes performed best for almost all metrics, showing an AUC of 0.737 compared to 0.718 without APOE genotypes.

[0241] [Table 22]

[0242] Models fitted to the APOE-only training data have consistently low sensitivity values when using a cutoff value of 0.16 (Table 18, above). This indicates that the predicted probabilities based on the APOE-only training data are lower than those based on the complete data. For comparison, Table 19 shows the sensitivity and specificity metrics when using the cutoff value that yields the highest Youden's J for the APOE-only training data.

[0243] [Table 23]

[0244] The model with only APOE as a feature showed the lowest AUC by a wide margin, with a difference of 0.109 between the APOE-only model fitted to only the APOE training data and the final model. In comparison, the performance difference between the final models with and without APOE was smaller, at 0.019. Both differences were statistically significant, as shown in Table 20, which shows the results of the paired Delong test. [Table 24]

[0245] Model performance metrics on the validation data for models fitted with and without APOE genotypes using a cutoff value of 0.16 are also presented in Table 21. Table 22 shows sensitivity and specificity metrics on the validation data using the cutoff value that gave the highest Youden's J evaluated on the APOE-only training data subset.

[0246] Note that performance on the validation data follows the same pattern as performance on the training data, with the APOE-only model having the lowest AUC and the final model + APOE having the highest AUC. As shown in Table 23, which shows the results of the paired Delong hypothesis tests, there is insufficient evidence that these differences in the validation data are statistically significant. [Table 25] [Table 26] [Table 27]

[0247] Example 5: Model validation plan and results Clinical Validation Plan: Validation will be evaluated on a holdout dataset of 15% of the unused ARIC Visit 3 data.

[0248] The model selected for refinement is an AFT model using a Weibull distribution with 25 features. The predicted absolute probability of dementia diagnosis risk 20 years after blood sampling is calculated using the selected model. The predictive performance of the model is required to demonstrate an AUC of at least 0.65, 0.66, 0.67, 0.678, 0.68, 0.69, 0.7, or higher in the validation dataset 20 years after blood sampling.

[0249] Clinical Outcomes in Validation Data. The required passing criterion for this model validation was that the mid-life dementia risk model exhibit an AUC of at least 0.65, 0.66, 0.67, 0.678, 0.68, 0.69, 0.7, or greater at 20 years after blood draw in the validation data set. As shown in Table 24, the model passed validation with an AUC at 20 years equal to 0.70.

[0250] [Table 28]

[0251] The model performance metrics on the validation data are slightly lower than those on the training or validation datasets, however the AUC is high enough to pass the performance criteria and the metrics are close to those on the training or validation datasets in all instances.

[0252] The simulation results in Table 25 below show that the best approach to handle outlying aptamers is imputation with zero value replacement. For this reason, it is recommended to use the mean value, zero value, for imputation.

[0253] [Table 29]

[0254] The 95% and 99% upper and lower bounds of the variability of the model predictions due to analysis with the training data are listed in Table 26 below.

[0255] [Table 30]

[0256] Example 6: Multiplexed aptamer assays and statistical approaches for biomarker identification

[0257] A multiplex aptamer assay was used to analyze test samples and control samples to identify biomarkers that predict dementia risk within 5 years.The multiplex analysis used in this experiment included aptamers for detecting approximately 5,000 proteins in blood from a small sample volume (approximately 65 μl of serum or plasma) with a low detection limit (median 1 pM), a dynamic range of approximately 7 logs, and a median coefficient of variation of approximately 5%.Multiplex aptamer assays are generally described, for example, in Gold et al.(2010) Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery.PLoS ONE 5(12):e15004; and US Patent Application Publication Nos. 2012 / 0101002 and 2012 / 0077695.

[0258] Example 7: Model Specification

[0259] The endpoint for these analyses was the time-to-onset dementia outcome, which has two components: 1) the time in days from blood draw to diagnosis of dementia (by Level 3 adjudication methods including cognitive assessment testing, telephone screening, informant assessment, hospital records, and death record review) or study discontinuation / completion, and 2) a binary variable indicating whether a Level 3 dementia diagnosis was observed during the study period.

[0260] The model selected was an accelerated mortality time (AFT) model with a Weibull distribution of 25 signature proteins (see Table 6) applied to predict the risk of being diagnosed with dementia within 5 years. The uncalibrated model was applied to the entire study period of ARIC visit 5 to maximize performance at 5 years. The final calibrated risk (CR) is a piecewise linear transformation of the 5-year prediction (uncalibrated risk; UCR) from the 20-year midlife dementia risk model, restricting the predicted probability to 0–1.

[0261] The model provides two predictions:

[0262] 1. Absolute Risk:

[0263] This output is the calibrated absolute risk generated by the midlife dementia risk model. Absolute risk is calculated by generating the survival model output, which is the absolute probability of not being diagnosed with dementia within 5 years (traditional Pr [dementia-free], values between 0 and 1). The resulting predicted probability is then subtracted from 1 to obtain the 5-year absolute probability of being diagnosed with dementia. This risk probability is then calibrated using the calibration equation described previously. The absolute risk probability is precisely bounded with upper and lower limits of 0.000001 (rounded to 0.000) and 0.999999 (rounded to 1.000).

[0264] 2. Relative risk:

[0265] This is a continuous variable calculated using the absolute risk probabilities generated by the model (above) divided by the "baseline" absolute probability (defined below) in the training cohort. This approach allows the model's risk probability predictions to be interpreted such that higher values indicate a higher likelihood of being diagnosed with dementia within the next five years.

[0266] The baseline risk probability for the calibrated model represents the absolute risk for the "average" person in the training cohort. Using the training dataset, mean protein measurements (log10 [RFU]) representing the proteomic profile of a "baseline" individual were derived for each model protein. The baseline absolute risk probability was calculated by applying the "baseline" proteomic profile to the calibrated 5-year dementia risk model. Therefore, based on the "baseline" proteomic profile, a relative risk score of less than 1 represents a lower than average risk, and a relative risk score of more than 1 represents a higher than average risk. The 5-year dementia diagnosis rate for individuals over 65 years old in the ARIC dataset is consistent with the dementia event rate for the US population of the same age as the intended use population.

[0267] The baseline absolute risk score on the calibrated training data is 0.062842 or approximately 6.3%.

[0268] The relative risk scores (where relative risk is the absolute risk divided by the baseline absolute risk of 0.062842) and absolute risk scores were stratified into four corresponding clinically meaningful risk categories corresponding to the binning in the training dataset used in the 20-year midlife dementia risk test. Kaplan-Meier (KM) plots spanning the entire study period (6.5 years) at ARIC Visit 5 were generated for these risk bins in the training and validation datasets. Note that the first two risk bins (low and intermediate-low) correspond to individuals with a predicted risk of dementia diagnosis lower than the average risk based on our data (baseline score of 0.062842, relative risk of 1 or less), while the intermediate-high and high risk bins correspond to predicted risks higher than the mean / baseline.

[0269] A summary of the relative risk stratification and corresponding event rates is shown in Table 27. Both raw and KM event rates are shown, with KM event rates taking into account censoring.

[0270] [Table 31]

[0271] Scoring rules for risk binning based on relative risk for the dementia risk test at 5 years are shown in Table 28a, and scoring rules for values reported in the LDT are shown in Table 28b.

[0272] [Table 32]

[0273] [Table 33]

[0274] To assess the calibration of the 5-year dementia risk test model, we generated KM plots comparing the KM estimates of observed event rates stratified by risk deciles with the absolute predicted probabilities of the final model. Note that the error bars generally lie near the 45-degree line, indicating that the mean model-predicted probabilities accurately represent the event rates observed in the training data and that the model is well calibrated. Additionally, the goodness-of-fit of the calibrated 5-year dementia risk model was assessed using the Hosmer-Lemeshow (HL) test. A high p-value indicates a lack of evidence of poor calibration. When calculated using quintiles, the model exhibited HL test p-values of 0.080 and 0.273 in the training and validation sets, respectively, suggesting good overall calibration of the model.

[0275] Model outputs are calibrated absolute risks (1-Pr(dementia-free)) derived from a 20-year midlife dementia risk model and applied to 5 years. The 5-year event probability is reported as a continuous variable. Because the output of this model is a probability, values outside the range [0,1] are malfunctions and will not be reported. [Table 34]

[0276] Risk Binning Rules in LDT: As an example, a relative risk (RR) value is reported to the patient and used for binning and risk label assignment. Relative risk is calculated by taking the absolute risk (AR), then rounding and dividing by the baseline risk (BR, BR=0.062842). The relative risk is then used to stratify predictions into four risk bins ("low," "medium-low," "medium-high," and "high" risk).

[0277] Relative risk reporting rules in LDT: As an example, for ease of understanding for patients, relative risk values less than 1.0 are reported differently than relative risk values greater than 1.0. Therefore, the binning procedure and reported values are categorized into three components (RR<1.0, RR=1.0, RR>1.0).

[0278] In all three cases, the first two steps are: 1. Round RR. a. For RR less than 1.0, round RR to two decimal places. b. For RRs greater than or equal to 1.0, round the RR to one decimal place. 2. Assign bin labels based on the rules in Table 3a. The values reported to the clinician / patient differ based on three relative risk categories (different from relative risk bins), which are as follows and shown in Table 3b: 3. Rounded RRs less than 1.0 If the rounded RR is less than 0.25, the value reported to the patient is "less than 75% risk compared to the average." b. If the rounded RR is 0.25 or greater and less than 1.0, the value reported to the patient is calculated as percent risk reduction = 100% (├1 - [RR rounded by (1a)]┤), and the patient is told, "Your risk is [percent risk reduction] lower than average." Rounded RR equal to 4.1.0 a. "The patient is at average risk." Rounded RRs above 5.1.0 a. Report the value to the patient as "[RR rounded by (1b)] times higher risk compared to the mean."

[0279] Example of LDT usage: A hypothetical patient has a predicted absolute probability based on a proteomic model equal to 0.023456. The relative risk for this patient, rounded to two decimal places, is 0.37, which is less than 1, so it is converted to a percentage and reported as a 63% lower risk compared to the average. This relative risk score corresponds to the "low" risk bin.

number

[0280] LDT Usage Example 2: A hypothetical patient has a predicted absolute probability based on a proteomic model equal to 0.760489. The relative risk for this patient, rounded to one decimal place, is 12.1, which exceeds 1 and is therefore reported as a 12.1-fold increased risk compared to the average. This relative risk score corresponds to the "high" risk bin.

number

[0281] This relative risk in this example can be interpreted as follows: this patient's risk of dementia diagnosis at 5 years is 12.1 times higher compared to our reference population, which has an observed event rate of 8.6%.

[0282] Example 8: Dataset for test development and validation

[0283] Development and Validation Cohort(s). The Atherosclerosis Risk in Communities (ARIC) study is a prospective epidemiological study conducted in four communities in the United States: Forsyth County, NC; Jackson, MS; the northwest suburbs of Minneapolis, MN; and Washington County, MD. The ARIC trial enrolled 15,792 participants aged 45-64 years. Enrollment occurred from 1987 to 1989, and follow-up is currently ongoing for 30 years, with study visit 7 in 2018-2019. The ARIC trial was originally designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic disease, and differences in cardiovascular risk factors, medical care, and disease by race, sex, location, and date. However, the trial was expanded to facilitate epidemiological studies of dementia (Knopman et al., Alzheimer's Dement (Amst), 2016;2:1-11). Dementia diagnoses (including Alzheimer's disease, cerebrovascular disease-related dementia, Lewy body-related dementia, or undefined dementia) were determined (considered Level 3) through cognitive assessment tests, telephone screening, informant assessment, hospital records, and death record review. The average age at onset of all new cases of dementia in the United States is 83.7 years. The 20-year midlife dementia risk model was constructed using the ARIC Visit 3 sample (mean age 60.2 years), while the 5-year dementia risk model was calibrated from the 20-year midlife dementia risk model using the ARIC Visit 5 sample, which includes 6 years of follow-up data collected from individuals aged 66-90 years (mean age 75.6 years) between 2011 and 2013. The model aimed to predict dementia diagnosis risk up to 5 years from blood sampling, and therefore, performance metrics of the model were evaluated at 5 years.

[0284] While the prevalence of dementia in people over 65 in the United States is nearly 11%; 4The age-adjusted prevalence of any dementia in individuals over 65 years of age in Europe is estimated to be 6.4% (Lobo et al., Neurology, 2000;54(11 Suppl 5):S4-S9). Dementia rates increase with age; for example, the prevalence of Alzheimer's disease-specific dementia is 5.3% in individuals aged 65-74 years, 13.8% in individuals aged 75-84 years, and 34.6% in individuals over 85 years of age (Alzheimer's Association Report, 2021, Alzheimer's Dement, 2021;17(3):327-406). In this dataset consisting of individuals over 65 years of age (66-90 years, mean age at blood draw 75.6 years), the mean event rate of developing dementia within a 5-year period was 8.6%, and the baseline absolute risk derived from the proteomic model was 6.3%. These values generally correspond to the range of prevalence estimates across the United States and Europe.

[0285] Dataset stratification. In this study, the data was split into three independent sets (70% training / 15% validation / 15%), and the entire dataset was stratified by dementia diagnosis (event vs. no event) as the endpoint, as described by Escott-Price et al. (Escott-Price V, et al. Brain. 2015;138(12):3673-3684). The validation dataset was not used in the POC or refinement phases.

[0286] Model development data

[0287] [Table 35]

[0288] [Table 36]

[0289] Model Validation Data

[0290] [Table 37]

[0291] [Table 38]

[0292] * Individuals were considered censored if their last follow-up occurred before the end of the time interval (5 years from blood sampling). † Kaplan-Meier event rates account for the dropout of individuals who are censored before the end of the time interval.

[0293] Model Validation Data

[0294] [Table 39]

[0295] [Table 40]

[0296] * Individuals were considered censored if their last follow-up occurred before the end of the time interval (5 years from blood sampling). † Kaplan-Meier event rates account for the dropout of individuals who are censored before the end of the time interval.

[0297] Development Results

[0298] Data QC and Pre-Analysis Results. At ARIC Visit 5, there were 5,024 samples with clinical endpoint data. Proteomics data was not available for 8 of these samples (0.159%). There were 5,016 total samples that had both clinical and v4.0 proteomics data. There were no significant associations between clinical covariates (gender, age, ethnicity, and APOE genotype) and the normalization scale factor. The following number of samples were removed based on various flags:

[0299] [Table 41]

[0300] NOTE: An outlier is a sample in which more than 5% of analyte measurements exceed 6 median absolute deviations from the median. A RowCheck failure is a sample in which at least one scale factor falls outside the acceptable range of 0.4–2.5.

[0301] Additionally, 363 analytes that failed target confirmation specificity testing were removed prior to analysis, leaving 4921 analytes available for analysis. No other issues were identified during data QC or pre-analysis. Samples in this study were analyzed with the analyte assay from September 1, 2018, to October 16, 2018.

[0302] POC approach and results.

[0303] The 20-year mid-life dementia risk model is a Weibull AFT survival model developed in the ARIC Visit 3 dataset. The 20-year model was used to predict 5-year dementia risk for individuals in the ARIC Visit 5 dataset, an older population. Although these predictions produced good risk rankings (e.g., individuals with lower predicted risks tended to have lower event rates), these predictions were not well calibrated.

[0304] The best-performing calibration method in the POC analysis was linear scaling fitted to 20 quantiles, which demonstrated an AUC of 0.799 (confidence interval of 0.748–0.802), exceeding our success criterion of an AUC of 0.678 or greater. The PEC for this model was 0.081 (confidence interval of 0.072–0.090), and the Hosmer-Lemeshow test p-value was 0.123 (a p-value greater than 0.05 indicates a lack of evidence against good calibration). These results indicate that the model is well calibrated. Furthermore, the 95% confidence intervals for the KM event rates in the calibration plot capture the mean predicted risk for all 10 deciles.

[0305] Improved approach and results.

[0306] The refined, calibrated 5-year dementia risk model was developed using training and validation splits from the proof-of-concept (POC) ARIC Visit 5 dataset. Individuals in these sets were aged 66-90 years. Individuals diagnosed with dementia at the time of blood draw were excluded from this model development. Individuals with mild cognitive impairment (MCI) at the time of blood draw were not excluded.

[0307] Refinement analyses pursued calibration of the 20-year midlife dementia risk model developed at ARIC Visit 3 to predict dementia risk within 20 years in an older population (ARIC Visit 5) to predict dementia risk within 5 years. The 20-year midlife dementia risk model is a Weibull AFT model using 25 analytes. Uncalibrated predictions on the development data were obtained by predicting dementia risk at 5 years (1,825 days) using the 20-year midlife dementia risk model. POC results indicate that these predictions significantly underpredicted the observed event rates.

[0308] A calibration function (e.g., a function that converts uncalibrated predicted risk to calibrated predicted risk) was fitted by first categorizing the predicted probabilities into quantiles and then using linear regression to find the line of best fit between the predicted risk mean and the KM event rate for each quantile. The linear regression fit was weighted based on the width of the confidence interval for the KM event rate. Quantiles with small confidence intervals were weighted more heavily than quantiles with larger confidence intervals.

[0309] The final calibration function is calculated using the 20th quantile and

number

[0310] These tuning parameters (power in terms of weights and number of quantiles) were selected by 10-fold cross-validation with 5 replicates, optimizing for the p-value of the Hosmer-Lemeshow test. However, cross-validated performance was similar across all parameter combinations.

[0311] We chose a piecewise-defined calibration function to constrain the calibrated probabilities to be between 0 and 1. Without upper and lower bounds on the uncalibrated predictions, the calibrated predictions are not guaranteed to be between 0 and 1.

[0312] The final calibrated risk (CR) is therefore a piecewise linear transformation of the 5-year prediction (uncalibrated risk; UCR) from the mid-life dementia risk model, restricting the predicted probability to 0–1. Specifically,

number

[0313] The performance metrics on the training and validation data evaluated at 5 years are shown in Table 33. The AUC values on training and validation meet the requirement of an AUC of 0.678 or greater.

[0314] [Table 42]

[0315] Performance compared to APOE.

[0316] The performance of the final model was compared with the ability of APOE genotype to predict an individual's 5-year dementia risk.

[0317] An APOE-only Weibull AFT model was fitted to a subset of the training data for which the APOE genotype was known. The performance of the APOE-only model was compared to the performance of a final model fitted to a subset of the training and validation samples for which the APOE genotype information was known.

[0318] APOE genotyping for the ε2, ε3, and ε4 alleles was performed only on a subset of ARIC participants, so model performance can only be performed on a subset of samples. However, 96.2% of the training samples and 94.7% of the validation samples from the ARIC Visit 5 dataset were assigned an APOE genotype (represented by the combination of the three alleles ε2, ε3, and ε4). Homozygotes for the ε2 allele were rare (N = 28), and only one sample with this genotype in the training dataset was diagnosed with dementia within 5 years. Therefore, in this model, samples with the E2 / E2 and E2 / E3 genotypes were combined into one category.

[0319] Model performance metrics are shown in Table 34, and the dynamic range is shown in Table 35. The calibrated 5-year dementia risk proteomic final model outperformed a model consisting of APOE genotype alone, with AUCs of 0.780 vs. 0.575 in the training sample and 0.726 vs. 0.564 in the validation sample, respectively.

[0320] [Table 43]

[0321] [Table 44]

[0322] * Event rates calculated for a subset of training data with known APOE genotypes.

[0323] Validation Plan

[0324] Clinical validation plan.

[0325] Validation will be evaluated on a holdout dataset of 15% of the unused ARIC Visit 5 data. The refined final model is a calibration function applied to a 20-year midlife dementia risk model, an AFT model using a Weibull distribution with 25 features. The predicted absolute probability of dementia diagnosis risk at 5 years after blood sampling will be calculated using the calibrated final model. The predictive performance of the model must demonstrate an AUC of at least 0.678 at 5 years after blood sampling in the validation dataset.

[0326] Validation result model

[0327] Clinical outcomes with validation data.

[0328] The required passing criterion for validation was that the 5-year dementia risk model exhibit an AUC of at least 0.678 at 5 years after blood draw using the validation dataset. As shown in Table 36, the model passed validation with an AUC at 5 years equal to 0.776.

[0329] [Table 45]

[0330] * The C statistic is time independent. † For the Hosmer-Lemeshow (HL) test, a p-value less than 0.05 indicates evidence of insufficient calibration.

[0331] The model performance metrics on the validation data are approximately the same or higher than those from the training or validation datasets.

[0332] Validation Conclusions: The final model is a recalibration of the 25-trait midlife dementia risk model to predict 5-year dementia diagnosis risk for adults aged 65 years and older. Model output in RUO is absolute risk probability, with possible scores ranging from 0.000 to 1.000. Model output in LDT is 1) the relative risk of dementia diagnosis compared to the average person in the reference population, and 2) the corresponding risk bin. Raw relative risk values range from 0.25 to 15.9, with values less than 1.0 converted to a percent lower risk and values greater than 1.0 reported as x-fold higher risk. Performance metrics in validation exceeded an AUC of 0.678 or greater.

[0333] Example 9: Analysis of biomarker panels in dementia models

[0334] Biomarker panels for models comprising various combinations of the biomarkers listed in Table 6 were analyzed to determine area under the curve (AUC) values for the various combinations. The biomarker panels for the models can be based on a panel of N biomarker proteins having an AUC value of at least 0.65, at least 0.66, at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.75, at least 0.8, at least 0.85, at least 0.9, or at least 0.95, where N is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and / or 25 of the biomarker proteins listed in Table 6. The following table shows exemplary model results when various combinations comprising 1 to 25 biomarker proteins were evaluated. [Table 46-1] [Table 46-2]

Table 46-3

Table 46-4

Table 46-5

Table 46-6

Table 46-7

Table 46-8

Table 46-9

Table 46-10

Table 46-11

Table 46-12

Table 46-13

Table 46-14

Table 46-15

Table 46-16

Table 46-17

Table 46-18

Table 46-19

Table 46-20

Table 46-21

Table 46-22

Table 46-23

Table 46-24

Table 46-25

Table 46-26

Table 46-27

Table 46-28

Table 46-29

Table 46-30

Table 47-1

Table 47-2

Table 48-1

Table 48-2

Table 48-3

Table 48-4

Table 48-5

Table 48-6

Table 48-7

Table 48-8

Table 48-9

Table 48-10

Table 48-11

Table 48-12

Table 48-13

Table 48-14

Table 48-15

Table 48-16

Table 48-17

Table 48-18

Table 48-19

Table 48-20

Table 48-21

Table 48-22

Table 48-23

Table 48-24

Table 48-25

Table 48-26

Table 48-27

Table 48-28

Table 48-29

Table 49-1

Table 49-2

Table 49-3

Table 49-4

Table 49-5

Table 49-6

Table 49-7

Table 49-8

Table 49-9

Table 49-10

Table 49-11

Table 49-12

Table 49-13

Table 49-14

Table 49-15

Table 49-16

Table 49-17

Table 49-18

Table 49-19

Table 49-20

Table 49-21

Table 49-22

Table 49-23

Table 49-24

Table 49-25

Table 49-26

Table 49-27

Table 49-28

Table 49-29

Table 50-1

Table 50-2

Table 50-3

Table 50-4

Table 50-5

Table 50-6

Table 50-7

Table 50-8

Table 50-9

Table 50-10

Table 50-11

Table 50-12

Table 50-13

Table 50-14

Table 50-15

Table 50-16

Table 50-17

Table 50-18

Table 50-19

Table 50-20

Table 50-21

Table 50-22

Table 50-23

Table 50-24

Table 50-25

Table 50-26

Table 50-27

Table 50-28

Table 50-29

Table 51-1

Table 51-2

Table 51-3

Table 51-4

Table 51-5

Table 51-6

Table 51-7

Table 51-8

Table 51-9

Table 51-10

Table 51-11

Table 51-12

Table 51-13

Table 51-14

Table 51-15

Table 51-16

Table 51-17

Table 51-18

Table 51-19

Table 51-20

Table 51-21

Table 51-22

Table 51-23

Table 51-24

Table 51-25

Table 51-26

Table 51-27

Table 51-28

Table 51-29

Table 51-30

Table 52-1

Table 52-2

Table 52-3

Table 52-4

Table 52-5

Table 52-6

Table 52-7

Table 52-8

Table 52-9

Table 52-10

Table 52-11

Table 52-12

Table 52-13

Table 52-14

Table 52-15

Table 52-16

Table 52-17

Table 52-18

Table 52-19

Table 52-20

Table 52-21

Table 52-22

Table 52-23

Table 52-24

Table 52-25

Table 52-26

Table 52-27

Table 52-28

Table 52-29

Table 52-30

Table 53-1

Table 53-2

Table 54-1

Table 54-2

Table 54-3

Table 54-4

Table 54-5

Table 54-6

Table 54-7

Table 54-8

Table 54-9

Table 54-10

Table 54-11

Table 54-12

Table 54-13

Table 54-14

Table 54-15

Table 54-16

Table 54-17

Table 54-18

Table 54-19

Table 54-20

Table 54-21

Table 54-22

Table 54-23

Table 54-24

Table 54-25

Table 54-26

Table 54-27

Table 55-1

Table 55-2

Table 55-3

Table 55-4

Table 55-5

Table 55-6

Table 55-7

Table 55-8

Table 55-9

Table 55-10

Table 55-11

Table 55-12

Table 55-13

Table 55-14

Table 55-15

Table 55-16

Table 55-17

Table 55-18

Table 55-19

Table 55-20

Table 55-21

Table 55-22

Table 55-23

Table 55-24

Table 55-25

Table 55-26

Table 55-27

Table 56-1

Table 56-2

Table 56-3

Table 56-4

Table 56-5

Table 56-6

Table 56-7

Table 56-8

Table 56-9

Table 56-10

Table 56-11

Table 56-12

Table 57-1

Table 57-2

Table 57-3

Table 57-4

Table 57-5

Table 57-6

Table 57-7

Table 57-8

Table 57-9

Table 57-10

Table 57-11

Table 57-12

Table 59-1

Table 59-2

Table 59-3

Table 59-4

Table 59-5

Table 59-6

Table 59-7

Table 59-8

Table 59-9

Table 59-10

Table 59-11

Table 59-12

Table 59-13

Table 59-14

Table 59-15

Table 59-16

Table 59-17

Table 59-18

Table 59-19

Table 59-20

Table 59-21

Table 59-22

Table 59-23

Table 59-24

Table 59-25

Table 59-26

Table 59-27

Table 59-28

Table 59-29

Table 59-30

Table 59-31

Table 59-32

Table 59-33

Table 59-34

Table 59-35

Table 59-36

Table 59-37

Table 59-38

Table 59-39

Table 59-40

Table 59-41

Table 59-42

Table 59-43

Table 59-44

Table 59-45

Table 59-46

Table 59-47

Table 59-48

Table 59-49

Table 59-50

Table 59-51

Table 60-1

Table 60-2

Table 61-1

Table 61-2

Claims

1. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject the level of a CILP2 biomarker protein and the level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at 8, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

2. 1. A method of detecting levels of N biomarker proteins in a sample, comprising obtaining the sample from a subject and detecting the level of each of the N biomarker proteins in the sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

3. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of a PTN biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, the N biomarker proteins are at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

4. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of a PH biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

5. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of Notch1 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

6. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting a level of a NADK biomarker protein and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 , at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

7. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting a level of a CDON biomarker protein and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 , at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

8. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject the level of MP2K2 biomarker protein and the level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 8, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

9. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of H2A3 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 , at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

10. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting a level of an IGFALS biomarker protein and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

11. 1. A method of determining whether a subject is at risk of developing dementia within a 20 year period, comprising detecting in a sample from the subject a level of S100A13 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

12. 10. A method according to any one of the preceding claims, wherein N is from 2 to 25, or N is from 3 to 25, or N is from 4 to 25, or N is from 5 to 25, or N is from 6 to 25, or N is from 7 to 25, or N is from 8 to 25, or N is from 9 to 25, or N is from 10 to 25, or N is from 11 to 25, or N is from 12 to 25, or N is from 13 to 25, or N is from 14 to 25, or N is from 15 to 25.

13. 10. A method according to any one of the preceding claims, wherein N is 2, or N is 3, or N is 4, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10, or N is 11, or N is 12, or N is 13, or N is 14, or N is 15, or N is 16, or N is 17, or N is 18, or N is 19, or N is 20, or N is 21, or N is 22, or N is 23, or N is 24, or N is 25.

14. 10. The method of any one of the preceding claims, wherein each of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

15. 10. The method of any one of the preceding claims, wherein at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

16. 10. The method of any one of the preceding claims, wherein at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 of the N protein biomarkers are selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

17. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are CILP2 and H2A3, or two of the N biomarker proteins are CILP2 and IGFALS, or two of the N biomarker proteins are CILP2 and MP2K2, or two of the N biomarker proteins are CILP2 and NADK, or two of the N biomarker proteins are CILP2 and Notch1, or two of the N biomarker proteins are CILP2 and PH, or two of the N biomarker proteins are CILP2 and PTN, or two of the N biomarker proteins are CILP2 and S100A13, or two of the N biomarker proteins are CILP2 and CDON.

18. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are PTN and PH, or two of the or N biomarker proteins are PTN and S100A13, or two of the N biomarker proteins are PTN and Notch1, or two of the N biomarker proteins are PTN and NADK, or two of the N biomarker proteins are PTN and MP2K2, or two of the N biomarker proteins are PTN and IGFALS, or two of the N biomarker proteins are PTN and H2A3, or two of the N biomarker proteins are PTN and CDON.

19. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are PH and Notch1, or two of the N biomarker proteins are PH and NADK, or two of the N biomarker proteins are PH and CDON, or two of the N biomarker proteins are PH and MP2K2, or two of the N biomarker proteins are PH and H2A3, or two of the N biomarker proteins are PH and IGFALS, or two of the N biomarker proteins are PH and S100A13.

20. 2. A method according to any one of the preceding claims, wherein two of the N biomarker proteins are Notch1 and NADK, or two of the N biomarker proteins are Notch1 and CDON, or two of the N biomarker proteins are Notch1 and MP2K2, or two of the N biomarker proteins are Notch1 and H2A3, or two of the N biomarker proteins are Notch1 and IGFALS, or two of the N biomarker proteins are Notch1 and S100A13.

21. 2. The method of any one of the preceding claims, wherein two of the N biomarker proteins are NADK and CDON, or two of the N biomarker proteins are NADK and MP2K2, or two of the N biomarker proteins are NADK and H2A3, or two of the N biomarker proteins are NADK and IGFALS, or two of the N biomarker proteins are NADK and S100A13.

22. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are CDON and MP2K2, or two of the N biomarker proteins are CDON and H2A3, or two of the N biomarker proteins are CDON and IGFALS, or two of the N biomarker proteins are CDON and S100A13.

23. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are MP2K2 and H2A3, or two of the N biomarker proteins are MP2K2 and IGFALS, or two of the N biomarker proteins are MP2K2 and S100A13.

24. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are H2A3 and IGFALS, or two of the N biomarker proteins are H2A3 and S100A13.

25. 10. The method of any one of the preceding claims, wherein two of the N biomarker proteins are IGFALS and S100A13.

26. 10. The method of any one of the preceding claims, wherein the sample is a blood sample, a plasma sample, or a serum sample.

27. 10. The method of any one of the preceding claims, wherein the subject is 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 years old or older.

28. 10. The method of any one of the preceding claims, wherein detection is performed using mass spectrometry, an aptamer-based assay, and / or an antibody-based assay.

29. 10. The method of any one of the preceding claims, wherein the method comprises contacting biomarker proteins of the sample or samples with a set of biomarker capture reagents, each biomarker capture reagent of the set of biomarker capture reagents specifically binding to a different biomarker protein to be detected.

30. 30. The method of claim 29, wherein each biomarker capture reagent is an antibody or an aptamer.

31. 31. The method of claim 30, wherein each biomarker capture reagent is an aptamer.

32. 32. The method of claim 31, wherein at least one aptamer is a slow off-rate aptamer.

33. 33. The method of claim 32, wherein the at least one slow off-rate aptamer comprises nucleotides having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 modifications.

34. 34. The method of claim 32 or claim 33, wherein each slow off-rate aptamer binds to its target protein with an off-rate (t1 / 2) of 20 minutes or less, 30 minutes or less, 60 minutes or less, 90 minutes or less, 120 minutes or less, 150 minutes or less, 180 minutes or less, 210 minutes or less, or 240 minutes or less.

35. 35. The method of any one of claims 28 to 34, wherein the level of each measured biomarker protein is determined by relative fluorescence units (RFU) or protein concentration.

36. 10. The method of any one of the preceding claims, wherein determining the risk of developing dementia within a 20 year period is based on input of the levels of the N biomarker proteins measured in a statistical model.

37. 37. The method of claim 36, wherein said determining comprises analyzing said levels of said N biomarker proteins using an accelerated death time (AFT) model with a Weibull distribution.

38. 38. The method of claim 36 or 37, wherein the model has an area under the curve (AUC) selected from at least 0.65, at least 0.66, at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.75, at least 0.8, at least 0.85, at least 0.9, or at least 0.

95.

39. 39. The method of any one of claims 36 to 38, wherein the model provides absolute risk probabilities of being diagnosed with dementia within 20 years.

40. 39. The method of any one of claims 36 to 38, wherein the model provides a calculation of the relative risk probability of being diagnosed with dementia within 20 years.

41. 41. The method of claim 40, wherein the relative risk is a range of values used to predict the onset of dementia within 20 years.

42. 42. The method of claim 41, wherein the relative risk is selected from low to high.

43. 43. The method of any one of claims 40 to 42, wherein the range of relative risks is 0.25 to 6.

67.

44. 44. The method of any one of claims 36 to 43, wherein the model provides an absolute probability or relative risk prediction of dementia onset within a 20 year time period based on the level of each of proteins selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

45. 10. The method of any one of the preceding claims, wherein said subject is identified as being at risk of developing dementia within said 20 year period.

46. 46. The method of claim 45, further comprising administering a treatment to the subject.

47. 47. The method of claim 46, wherein the treatment comprises implementing a healthy diet, exercise, social and cognitive stimulation, and / or reducing vascular disease risk factors.

48. 48. The method of any one of claims 45-47, further comprising monitoring the subject at one or more additional time points to determine the risk of developing dementia within the 20 year period.

49. 46. The method of claim 45, wherein the subject is stratified in a preventative treatment trial.

50. 46. The method of claim 45, wherein a second diagnostic test is administered to the subject.

51. 51. The method of claim 50, wherein the second diagnostic test is an APOE diagnostic test, optionally wherein the second diagnostic test is an APOE genotyping test, optionally wherein the APOE genotyping test measures the ε2, ε3, and ε4 alleles.

52. 46. The method of claim 45, wherein the subject at risk of developing dementia within a 20 year period is identified for the purpose of making life planning and / or financial planning decisions.

53. 46. The method of claim 45, wherein one or more additional biomarkers associated with dementia are identified in a subject at risk of or with dementia.

54. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject the level of CILP2 biomarker protein and the level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

55. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject a level of PTN biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

56. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting the level of a PH biomarker protein and the level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

57. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject a level of Notch1 biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17. , at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

58. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject a level of a NADK biomarker protein and a level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

59. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting a level of a CDON biomarker protein and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

60. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting in a sample from the subject the level of MP2K2 biomarker protein and the level of each of N biomarker proteins, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, the N biomarker proteins are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

61. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting the level of H2A3 biomarker protein and the level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

62. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting a level of an IGFALS biomarker protein and a level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17 , at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

63. 1. A method of determining whether a subject is at risk of developing dementia within a 5, 10, and / or 15 year period, comprising detecting the level of S100A13 biomarker protein and the level of each of N biomarker proteins in a sample from the subject, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at 7, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25, and at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

64. 64. The method of any one of claims 54 to 63, wherein N is 2 to 25, or N is 3 to 25, or N is 4 to 25, or N is 5 to 25, or N is 6 to 25, or N is 7 to 25, or N is 8 to 25, or N is 9 to 25, or N is 10 to 25, or N is 11 to 25, or N is 12 to 25, or N is 13 to 25, or N is 14 to 25, or N is 15 to 25.

65. 65. The method of any one of claims 54 to 64, wherein N is 2, or N is 3, or N is 4, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10, or N is 11, or N is 12, or N is 13, or N is 14, or N is 15, or N is 16, or N is 17, or N is 18, or N is 19, or N is 20, or N is 21, or N is 22, or N is 23, or N is 24, or N is 25.

66. 66. The method of any one of claims 54 to 65, wherein each of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

67. 66. The method of any one of claims 54 to 65, wherein at least one of the N biomarker proteins is selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

68. 66. The method of any one of claims 54 to 65, wherein at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 of the N protein biomarkers are selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

69. 66. The method of any one of claims 54 to 65, wherein two of the N biomarker proteins are CILP2 and H2A3, or two of the N biomarker proteins are CILP2 and IGFALS, or two of the N biomarker proteins are CILP2 and MP2K2, or two of the N biomarker proteins are CILP2 and NADK, or two of the N biomarker proteins are CILP2 and Notch1, or two of the N biomarker proteins are CILP2 and PH, or two of the N biomarker proteins are CILP2 and PTN, or two of the N biomarker proteins are CILP2 and S100A13, or two of the N biomarker proteins are CILP2 and CDON.

70. 66. The method of any one of claims 54 to 65, wherein two of said N biomarker proteins are PTN and PH, or two of said or N biomarker proteins are PTN and S100A13, or two of said N biomarker proteins are PTN and Notch1, or two of said N biomarker proteins are PTN and NADK, or two of said N biomarker proteins are PTN and MP2K2, or two of said N biomarker proteins are PTN and IGFALS, or two of said N biomarker proteins are PTN and H2A3, or two of said N biomarker proteins are PTN and CDON.

71. 66. The method of any one of claims 54 to 65, wherein two of said N biomarker proteins are PH and Notch1, or two of said N biomarker proteins are PH and NADK, or two of said N biomarker proteins are PH and CDON, or two of said N biomarker proteins are PH and MP2K2, or two of said N biomarker proteins are PH and H2A3, or two of said N biomarker proteins are PH and IGFALS, or two of said N biomarker proteins are PH and S100A13.

72. 2. A method according to any one of the preceding claims, wherein two of the N biomarker proteins are Notch1 and NADK, or two of the N biomarker proteins are Notch1 and CDON, or two of the N biomarker proteins are Notch1 and MP2K2, or two of the N biomarker proteins are Notch1 and H2A3, or two of the N biomarker proteins are Notch1 and IGFALS, or two of the N biomarker proteins are Notch1 and S100A13.

73. 66. The method of any one of claims 54 to 65, wherein two of the N biomarker proteins are NADK and CDON, or two of the N biomarker proteins are NADK and MP2K2, or two of the N biomarker proteins are NADK and H2A3, or two of the N biomarker proteins are NADK and IGFALS, or two of the N biomarker proteins are NADK and S100A13.

74. 66. The method of any one of claims 54 to 65, wherein two of the N biomarker proteins are CDON and MP2K2, or two of the N biomarker proteins are CDON and H2A3, or two of the N biomarker proteins are CDON and IGFALS, or two of the N biomarker proteins are CDON and S100A13.

75. 66. The method of any one of claims 54 to 65, wherein two of the N biomarker proteins are MP2K2 and H2A3, or two of the N biomarker proteins are MP2K2 and IGFALS, or two of the N biomarker proteins are MP2K2 and S100A13.

76. 66. The method of any one of claims 54 to 65, wherein two of the N biomarker proteins are H2A3 and IGFALS, or two of the N biomarker proteins are H2A3 and S100A13.

77. 66. The method of any one of claims 54 to 65, wherein two of the N biomarker proteins are IGFALS and S100A13.

78. 78. The method of any one of claims 54 to 77, wherein the sample is a blood sample, a plasma sample, or a serum sample.

79. 79. The method of any one of claims 54-78, wherein the subject is 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 years old or older.

80. 80. The method of any one of claims 54 to 79, wherein detection is performed using mass spectrometry, an aptamer-based assay, and / or an antibody-based assay.

81. 81. The method of any one of claims 54-80, wherein the method comprises contacting biomarker proteins of the sample or samples with a set of biomarker capture reagents, each biomarker capture reagent of the set of biomarker capture reagents specifically binding to a different biomarker protein to be detected.

82. 82. The method of claim 81, wherein each biomarker capture reagent is an antibody or an aptamer.

83. 83. The method of claim 82, wherein each biomarker capture reagent is an aptamer.

84. 84. The method of claim 83, wherein at least one aptamer is a slow off-rate aptamer.

85. 85. The method of claim 84, wherein the at least one slow off-rate aptamer comprises nucleotides having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least 10 modifications.

86. 86. The method of claim 84 or claim 85, wherein each slow off-rate aptamer binds to its target protein with an off-rate (t1 / 2) of 20 minutes or less, 30 minutes or less, 60 minutes or less, 90 minutes or less, 120 minutes or less, 150 minutes or less, 180 minutes or less, 210 minutes or less, or 240 minutes or less.

87. 87. The method of any one of claims 80 to 86, wherein the level of each biomarker protein measured is determined by relative fluorescence units (RFU) or protein concentration.

88. 88. The method of any one of claims 54 to 87, wherein determining the risk of developing dementia within a 5, 10, and / or 15 year period is based on input of the levels of the N measured biomarker proteins into a statistical model.

89. 89. The method of claim 88, wherein said determining comprises analyzing said levels of said N biomarker proteins using an accelerated death time (AFT) model with a Weibull distribution.

90. 90. The method of claim 88 or 89, wherein the model has an area under the curve (AUC) selected from at least 0.65, at least 0.66, at least 0.67, at least 0.68, at least 0.69, at least 0.7, at least 0.75, at least 0.8, at least 0.85, at least 0.9, or at least 0.

95.

91. 91. The method of any one of claims 88 to 90, wherein the model provides absolute risk probabilities of being diagnosed with dementia within 5, 10, and / or 15 years.

92. 91. The method of any one of claims 88 to 90, wherein the model provides a calculation of relative risk probability of being diagnosed with dementia within 5, 10, and / or 15 years.

93. 93. The method of claim 92, wherein the relative risk is a range of values used to predict the onset of dementia within 5, 10, and / or 15 years.

94. 94. The method of claim 93, wherein the relative risk is selected from low to high.

95. 95. The method of any one of claims 92 to 94, wherein the range of relative risks is 0.25 to 6.

67.

96. 96. The method of any one of claims 88 to 95, wherein the model provides absolute probability or relative risk predictions of dementia onset within a 5, 10, and / or 15 year time period based on the level of each of proteins selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

97. 10. The method of any one of the preceding claims, wherein the subject is identified as being at risk of developing dementia within a 5, 10, and / or 15 year period.

98. 98. The method of claim 97, further comprising administering a treatment to the subject.

99. 99. The method of claim 98, wherein the treatment comprises implementing a healthy diet, exercise, social and cognitive stimulation, and / or reducing vascular disease risk factors.

100. 100. The method of any one of claims 97-99, further comprising monitoring the subject at one or more additional time points to determine the risk of developing dementia within the 5, 10, and / or 15 year time period.

101. 98. The method of claim 97, wherein the subject is stratified in a preventative treatment trial.

102. 98. The method of claim 97, wherein a second diagnostic test is administered to the subject.

103. 103. The method of claim 102, wherein the second diagnostic test is an APOE diagnostic test, optionally wherein the second diagnostic test is an APOE genotyping test, optionally wherein the APOE genotyping test measures the ε2, ε3, and ε4 alleles.

104. 98. The method of claim 97, wherein the subject at risk of developing dementia within the 5, 10, and / or 15 year time period is identified for the purpose of making life and / or financial planning decisions.

105. 98. The method of claim 97, wherein one or more additional biomarkers associated with dementia are identified in a subject at risk of or with dementia.

106. 106. The method of any one of claims 54 to 105, wherein said risk within a 5 year period is determined.

107. 106. The method of any one of claims 54 to 105, wherein the risk within a 10 year period is determined.

108. 106. The method of any one of claims 54 to 105, wherein said risk within a 15 year period is determined.

109. A kit comprising N biomarker protein capture reagents, wherein N is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least the kit comprises at most 25 biomarker protein capture reagents, wherein at least one of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

110. 110. The kit of claim 109, wherein N is 2 to 25, or N is 3 to 25, or N is 4 to 25, or N is 5 to 25, or N is 6 to 25, or N is 7 to 25, or N is 8 to 25, or N is 9 to 25, or N is 10 to 25, or N is 11 to 25, or N is 12 to 25, or N is 13 to 25, or N is 14 to 25, or N is 15 to 25.

111. 111. The kit of claim 109 or 110, wherein N is 2, or N is 3, or N is 4, or N is 5, or N is 6, or N is 7, or N is 8, or N is 9, or N is 10, or N is 11, or N is 12, or N is 13, or N is 14, or N is 15, or N is 16, or N is 17, or N is 18, or N is 19, or N is 20, or N is 21, or N is 22, or N is 23, or N is 24, or N is 25.

112. 112. The kit of any one of claims 109 to 111, wherein each of the N biomarker protein capture reagents specifically binds to a different biomarker protein.

113. The kit of any one of claims 109 to 112, wherein each of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2k2, H2A3, IGFALS, S100A13, NPTXR, TBCA, CDCP1, sRAGE, SVEP1, NDST1, ASB9, NFL, PARC, TIM-1, calgranulin B, YKL-40, IL-18, ATS13, and OPG.

114. The kit of any one of claims 109 to 113, wherein at least one of the N biomarker protein capture reagents specifically binds to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

115. 115. The kit of any one of claims 109 to 114, wherein at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or N at least 10 of the N biomarker protein capture reagents specifically bind to a biomarker protein selected from CILP2, PTN, PH, Notch1, NADK, CDON, MP2K2, H2A3, IGFALS, and S100A13.

116. Two of the N biomarker protein capture reagents specifically bind to CILP2 and H2A3, or two of the N biomarker protein capture reagents specifically bind to CILP2 and IGFALS, or two of the N biomarker protein capture reagents specifically bind to CILP2 and MP2K2, or two of the N biomarker protein capture reagents specifically bind to CILP2 and NADK, or two of the N biomarker protein capture reagents specifically bind to CILP2 and NADK. itch1, or two of the N biomarker protein capture reagents specifically bind to CILP2 and PH, or two of the N biomarker protein capture reagents specifically bind to CILP2 and PTN, or two of the N biomarker protein capture reagents specifically bind to CILP2 and S100A13, or two of the N biomarker protein capture reagents specifically bind to CILP2 and CDON.

117. 116. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to PTN and PH, or two of the N biomarker protein capture reagents specifically bind to PTN and S100A13, or two of the N biomarker protein capture reagents specifically bind to PTN and Notch1, or two of the N biomarker protein capture reagents specifically bind to PTN and NADK, or two of the N biomarker protein capture reagents specifically bind to PTN and MP2K2, or two of the N biomarker protein capture reagents specifically bind to PTN and IGFALS, or two of the N biomarker protein capture reagents specifically bind to PTN and H2A3, or two of the N biomarker protein capture reagents specifically bind to PTN and CDON.

118. 116. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to PH and Notch1, or two of the N biomarker protein capture reagents specifically bind to PH and NADK, or two of the N biomarker protein capture reagents specifically bind to PH and CDON, or two of the N biomarker protein capture reagents specifically bind to PH and MP2K2, or two of the N biomarker protein capture reagents specifically bind to PH and H2A3, or two of the N biomarker protein capture reagents specifically bind to PH and IGFALS, or two of the N biomarker protein capture reagents specifically bind to PH and S100A13.

119. The method of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to Notch1 and NADK, or two of the N biomarker protein capture reagents specifically bind to Notch1 and CDON, or two of the N biomarker protein capture reagents specifically bind to Notch1 and MP2K2, or two of the N biomarker protein capture reagents specifically bind to Notch1 and H2A3, or two of the N biomarker protein capture reagents specifically bind to Notch1 and IGFALS, or two of the N biomarker protein capture reagents specifically bind to Notch1 and S100A13.

120. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to NADK and CDON, or two of the N biomarker protein capture reagents specifically bind to NADK and MP2K2, or two of the N biomarker protein capture reagents specifically bind to NADK and H2A3, or two of the N biomarker protein capture reagents specifically bind to NADK and IGFALS, or two of the N biomarker protein capture reagents specifically bind to NADK and S100A13.

121. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to CDON and MP2K2, or two of the N biomarker protein capture reagents specifically bind to CDON and H2A3, or two of the N biomarker protein capture reagents specifically bind to CDON and IGFALS, or two of the N biomarker protein capture reagents specifically bind to CDON and S100A13.

122. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to MP2K2 and H2A3, or two of the N biomarker protein capture reagents specifically bind to MP2K2 and IGFALS, or two of the N biomarker protein capture reagents specifically bind to MP2K2 and S100A13.

123. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to H2A3 and IGFALS, or two of the N biomarker protein capture reagents specifically bind to H2A3 and S100A13.

124. The kit of any one of claims 109 to 115, wherein two of the N biomarker protein capture reagents specifically bind to IGFALS and S100A13.

125. A kit comprising N biomarker protein capture reagents, said kit comprising biomarker protein capture reagents for carrying out the method of any one of claims 1 to 108.

126. 126. The kit of any one of claims 109 to 125, wherein each of the N biomarker protein capture reagents is an antibody or an aptamer.

127. 127. The kit of claim 126, wherein each biomarker protein capture reagent is an aptamer.

128. The kit of claim 127, wherein at least one aptamer is a slow off-rate aptamer.

129. The kit of claim 128, wherein the at least one slow off-rate aptamer comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 modified nucleotides.

130. Each slow off rate aptamer has an off rate (t １／２ 130. The kit of claim 128 or claim 129, wherein the target protein is bound by a nucleotide sequence selected from the group consisting of nucleotides (A, B, C, D, E ...

131. 131. The kit of any one of claims 109 to 130, for use in detecting the N biomarker proteins in a sample derived from a subject.

132. 132. The kit of claim 131, used to determine whether the subject is at risk of developing dementia within a 5, 10, 15, and / or 20 year period.

Images